Cover page
Cover page - shares | 9 Months Ended | |
Sep. 30, 2023 | Oct. 31, 2023 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Sep. 30, 2023 | |
Document Transition Report | false | |
Entity File Number | 001-37586 | |
Entity Registrant Name | INGEVITY CORPORATION | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 47-4027764 | |
Entity Address, Address Line One | 4920 O'Hear Avenue Suite 400 | |
Entity Address, City or Town | North Charleston | |
Entity Address, State or Province | SC | |
Entity Address, Postal Zip Code | 29405 | |
City Area Code | 843 | |
Local Phone Number | 740-2300 | |
Title of 12(b) Security | Common Stock ($0.01 par value) | |
Trading Symbol | NGVT | |
Security Exchange Name | NYSE | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 36,231,266 | |
Amendment Flag | false | |
Document Fiscal Year Focus | 2023 | |
Document Fiscal Period Focus | Q3 | |
Entity Central Index Key | 0001653477 | |
Current Fiscal Year End Date | --12-31 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Income Statement [Abstract] | ||||
Net sales | $ 446 | $ 482 | $ 1,320.4 | $ 1,284.7 |
Cost of sales | 317 | 305.7 | 908 | 820 |
Gross profit | 129 | 176.3 | 412.4 | 464.7 |
Selling, general, and administrative expenses | 40 | 54.2 | 140.3 | 142.9 |
Research and technical expenses | 7.8 | 7.6 | 24.6 | 23.1 |
Restructuring and other (income) charges, net | 24.6 | 3.3 | 49.4 | 10.6 |
Acquisition-related costs | 0.1 | 1.9 | 3.8 | 1.9 |
Other (income) expense, net | 1.3 | 2 | (13.9) | (1) |
Interest expense, net | 23.1 | 11.5 | 64.3 | 37.3 |
Income (loss) before income taxes | 32.1 | 95.8 | 143.9 | 249.9 |
Provision (benefit) for income taxes | 6.9 | 20.4 | 32.5 | 53.9 |
Net income (loss) | $ 25.2 | $ 75.4 | $ 111.4 | $ 196 |
Per share data | ||||
Basic earnings (loss) per share (usd per share) | $ 0.70 | $ 1.99 | $ 3.05 | $ 5.10 |
Diluted earnings (loss) per share (usd per share) | $ 0.69 | $ 1.98 | $ 3.03 | $ 5.06 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Statement of Comprehensive Income [Abstract] | ||||
Net income (loss) | $ 25.2 | $ 75.4 | $ 111.4 | $ 196 |
Foreign currency adjustments: | ||||
Foreign currency translation adjustment | (21.4) | (55.3) | (6.9) | (124.9) |
Unrealized gain (loss) on net investment hedges, net of tax provision (benefit) of zero, $1.0, zero, $3.2 | 0 | 3.4 | 0 | 10.7 |
Total foreign currency adjustments, net of tax provision (benefit) of zero, $1.0, zero, $3.2 | (21.4) | (51.9) | (6.9) | (114.2) |
Derivative instruments: | ||||
Unrealized gain (loss), net of tax provision (benefit) of $(0.1), $0.8, $(0.8), $3.5 | (0.1) | 2.7 | (2.5) | 11.4 |
Reclassifications of deferred derivative instruments (gain) loss, included in net income (loss), net of tax (provision) benefit of $0.3, $(0.7), $0.7, $(1.7) | 1.1 | (2.4) | 2.2 | (5.7) |
Total derivative instruments, net of tax provision (benefit) of $0.2, $0.1, $(0.1), $1.8 | 1 | 0.3 | (0.3) | 5.7 |
Pension & other postretirement benefits: | ||||
Reclassifications of net actuarial and other (gain) loss and amortization of prior service cost, included in net income, net of tax of zero for all periods | 0 | 0 | 0.1 | 0.1 |
Total pension and other postretirement benefits, net of tax of zero for all periods | 0 | 0 | 0.1 | 0.1 |
Other comprehensive income (loss), net of tax provision (benefit) of $0.2, $1.1, $(0.1), $5.0 | (20.4) | (51.6) | (7.1) | (108.4) |
Comprehensive income (loss) | $ 4.8 | $ 23.8 | $ 104.3 | $ 87.6 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) (Parenthetical) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Statement of Comprehensive Income [Abstract] | ||||
Tax on net investment hedge | $ 0 | $ 1,000,000 | $ 0 | $ 3,200,000 |
Foreign currency tax | 0 | 1,000,000 | 0 | 3,200,000 |
Unrealized tax (benefit) expense, derivative instruments | (100,000) | 800,000 | (800,000) | 3,500,000 |
Reclassifications tax expense (benefit), derivative instruments | 300,000 | (700,000) | 700,000 | (1,700,000) |
Total derivative instruments tax (benefit) expense | 200,000 | 100,000 | (100,000) | 1,800,000 |
Reclassifications of net actuarial and other (gain) loss and amortization of prior service cost, tax | 0 | 0 | 0 | 0 |
Total pension and other postretirement benefits, tax | 0 | 0 | 0 | 0 |
Other comprehensive income (loss), tax | $ 200,000 | $ 1,100,000 | $ (100,000) | $ 5,000,000 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) $ in Millions | Sep. 30, 2023 | Dec. 31, 2022 |
Assets | ||
Cash and cash equivalents | $ 84.5 | $ 76.7 |
Accounts receivable, net of allowance for credit losses of $0.5 - 2023 and $0.5 - 2022 | 216.6 | 224.8 |
Inventories, net | 386.7 | 335 |
Prepaid and other current assets | 46.7 | 42.5 |
Current assets | 734.5 | 679 |
Property, plant, and equipment, net | 800 | 798.6 |
Operating lease assets, net | 68.7 | 56.6 |
Goodwill | 520.1 | 518.5 |
Other intangibles, net | 375.6 | 404.8 |
Deferred income taxes | 6.1 | 5.7 |
Restricted investment, net of allowance for credit losses of $0.3 - 2023 and $0.6 - 2022 | 80.2 | 78 |
Strategic investments | 99.3 | 109.8 |
Other assets | 82.3 | 85.5 |
Total Assets | 2,766.8 | 2,736.5 |
Liabilities | ||
Accounts payable | 197.3 | 174.8 |
Accrued expenses | 64.5 | 54.4 |
Accrued payroll and employee benefits | 16.5 | 53.3 |
Current operating lease liabilities | 18.4 | 16.5 |
Notes payable and current maturities of long-term debt | 3 | 0.9 |
Income taxes payable | 5.4 | 3.6 |
Current liabilities | 305.1 | 303.5 |
Long-term debt including finance lease obligations | 1,469.7 | 1,472.5 |
Noncurrent operating lease liabilities | 50.6 | 40.8 |
Deferred income taxes | 105 | 106.5 |
Other liabilities | 117.7 | 114.9 |
Total Liabilities | 2,048.1 | 2,038.2 |
Commitments and contingencies (Note 13) | ||
Equity | ||
Preferred stock (par value $0.01 per share; 50,000,000 shares authorized; zero issued and outstanding - 2023 and 2022) | 0 | 0 |
Common stock (par value $0.01 per share; 300,000,000 shares authorized; issued: 43,443,512 - 2023 and 43,228,172 - 2022; outstanding: 36,231,063 - 2023 and 37,298,989 - 2022) | 0.4 | 0.4 |
Additional paid-in capital | 162.6 | 153 |
Retained earnings | 1,119.1 | 1,007.7 |
Accumulated other comprehensive income (loss) | (53.9) | (46.8) |
Treasury stock, common stock, at cost (7,212,449 shares - 2023 and 5,929,183 shares - 2022) | (509.5) | (416) |
Total Equity | 718.7 | 698.3 |
Total Liabilities and Equity | $ 2,766.8 | $ 2,736.5 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Millions | Sep. 30, 2023 | Dec. 31, 2022 |
Statement of Financial Position [Abstract] | ||
Allowance for accounts receivable | $ 0.5 | $ 0.5 |
Held-to-maturity, allowance for credit loss | $ 0.3 | $ 0.6 |
Preferred stock, par value (usd per share) | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized (shares) | 50,000,000 | 50,000,000 |
Preferred stock, shares issued (shares) | 0 | 0 |
Preferred stock, shares outstanding (shares) | 0 | 0 |
Common stock, par value (usd per share) | $ 0.01 | $ 0.01 |
Common stock, shares authorized (shares) | 300,000,000 | 300,000,000 |
Common stock, shares issued (shares) | 43,443,512 | 43,228,172 |
Common stock shares outstanding (shares) | 36,231,063 | 37,298,989 |
Treasury stock (shares) | 7,212,449 | 5,929,183 |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | ||
Cash provided by (used in) operating activities: | |||
Net income (loss) | $ 111.4 | $ 196 | |
Adjustments to reconcile net income (loss) to cash provided by (used in) operating activities: | |||
Depreciation and amortization | 97.7 | 78.6 | |
Non cash operating lease costs | 13.8 | 13.5 | |
Deferred income taxes | (2.3) | (2.2) | |
Disposal/impairment of assets | 12.6 | 1.9 | |
LIFO reserve | 62.6 | 10.7 | |
Share-based compensation | 8.3 | 11.1 | |
Gain on sale of strategic investment | (19.3) | 0 | |
Other non-cash items | 14.8 | 13.3 | |
Changes in operating assets and liabilities, net of effect of acquisitions: | |||
Accounts receivable, net | 6.1 | (98.4) | |
Inventories, net | (118.1) | (63.3) | |
Prepaid and other current assets | (5.8) | (2.3) | |
Accounts payable | 20.6 | 48.2 | |
Accrued expenses | 9 | 5.3 | |
Accrued payroll and employee benefits | (36.7) | (2.7) | |
Income taxes | 4.2 | 10.1 | |
Pension contribution | (2) | 0 | |
Operating leases | (16.6) | (15.5) | |
Changes in other operating assets and liabilities, net | 0.2 | 10.6 | |
Net cash provided by (used in) operating activities | 160.5 | 214.9 | |
Cash provided by (used in) investing activities: | |||
Capital expenditures | (80.6) | (93.3) | |
Proceeds from sale of strategic investment | 31.5 | 0 | |
Purchase of strategic investment | (2.4) | (62.8) | |
Net investment hedge settlement | 0 | 14.7 | |
Other investing activities, net | (4.8) | (3.3) | |
Net cash provided by (used in) investing activities | (56.3) | (144.7) | |
Cash provided by (used in) financing activities: | |||
Proceeds from revolving credit facility | 237.1 | 788 | |
Payments on revolving credit facility | (240.1) | (279) | |
Payments on long-term borrowings | 0 | (628.1) | |
Debt issuance costs | 0 | (3) | |
Debt repayment costs | 0 | (3.8) | |
Finance lease obligations, net | (0.6) | (0.4) | |
Borrowings (repayments) of notes payable and other short-term borrowings, net | 2.4 | 0 | |
Tax payments related to withholdings on vested equity awards | (4.8) | (2.2) | |
Proceeds and withholdings from share-based compensation plans, net | 4.7 | 2.8 | |
Repurchases of common stock under publicly announced plan | (92.1) | (139.2) | |
Net cash provided by (used in) financing activities | (93.4) | (264.9) | |
Increase (decrease) in cash, cash equivalents, and restricted cash | 10.8 | (194.7) | |
Effect of exchange rate changes on cash | (3) | (8.6) | |
Change in cash, cash equivalents, and restricted cash | 7.8 | (203.3) | |
Cash, cash equivalents, and restricted cash at beginning of period | 77.3 | 276.1 | |
Cash, cash equivalents and restricted cash at end of period | [1] | 85.1 | 72.8 |
Supplemental cash flow information: | |||
Cash paid for interest, net of capitalized interest | 57.9 | 35.9 | |
Cash paid for income taxes, net of refunds | 27.9 | 42.6 | |
Purchases of property, plant, and equipment in accounts payable | 6.1 | 5.1 | |
Leased assets obtained in exchange for new finance lease liabilities | 0.2 | 0 | |
Leased assets obtained in exchange for new operating lease liabilities | $ 26 | $ 9.2 | |
[1]Includes restricted cash of $0.6 million and $0.5 million and cash and cash equivalents of $84.5 million and $72.3 million at September 30, 2023 and 2022, respectively. Restricted cash is included within "Prepaid and other current assets" within the condensed consolidated balance sheets. |
Condensed Consolidated Statem_5
Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) - USD ($) $ in Millions | Sep. 30, 2023 | Sep. 30, 2022 |
Statement of Cash Flows [Abstract] | ||
Restricted cash | $ 0.6 | $ 0.5 |
Cash and cash equivalents | $ 84.5 | $ 72.3 |
Background
Background | 9 Months Ended |
Sep. 30, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Background | Background Description of Business Ingevity Corporation ("Ingevity," "the Company," "we," "us," or "our") provides products and technologies that purify, protect, and enhance the world around us. Through a team of talented and experienced people, we develop, manufacture, and bring to market solutions that help customers solve complex problems and make the world more sustainable. During the first quarter of 2023, we realigned our segment reporting structure to increase transparency for our investors and better align with how our chief operating decision maker intends to measure segment operating performance and allocate resources across our operating segments. We separated our engineered polymers product line from the Performance Chemicals reportable segment into its own reportable segment, Advanced Polymer Technologies. This reportable segment change also resulted in our Performance Chemicals reporting unit for goodwill being split into two separate reporting units for the purposes of goodwill impairment testing. We operate in three reportable segments: Performance Chemicals, which includes specialty chemicals and pavement technologies; Advanced Polymer Technologies, which includes biodegradable plastics and polyurethane materials; and Performance Materials, which includes activated carbon. Our products are used in a variety of demanding applications, including adhesives, agrochemicals, asphalt paving, bioplastics, coatings, elastomers, lubricants, pavement markings, publication inks, oil exploration and production and automotive components. Basis of Consolidation and Presentation These unaudited Condensed Consolidated Financial Statements reflect the consolidated operations of the Company and have been prepared in accordance with United States Securities and Exchange Commission ("SEC") interim reporting requirements. Accordingly, the accompanying Condensed Consolidated Financial Statements do not include all disclosures required by accounting principles generally accepted in the United States of America ("GAAP") for full financial statements and should be read in conjunction with the Annual Consolidated Financial Statements for the years ended December 31, 2022, 2021 and 2020, collectively referred to as the “Annual Consolidated Financial Statements,” included in our Annual Report on Form 10-K for the year ended December 31, 2022 (the "2022 Annual Report"). In the opinion of management, the Condensed Consolidated Financial Statements contain all adjustments which include only normal recurring adjustments necessary to fairly state the condensed consolidated results for the interim periods presented. The consolidated results of operations for interim periods are not necessarily indicative of the results to be expected for the full year. The preparation of the Condensed Consolidated Financial Statements requires management to make estimates and assumptions with respect to the reported amounts of assets, liabilities, revenue, and expenses and the disclosure of contingent assets and liabilities. Actual results could differ from these estimates. Certain prior year amounts have been reclassified to conform with the current year's presentation. |
New Accounting Guidance
New Accounting Guidance | 9 Months Ended |
Sep. 30, 2023 | |
Accounting Policies [Abstract] | |
New Accounting Guidance | New Accounting GuidanceThe Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC" or "Codification") is the sole source of authoritative GAAP other than SEC issued rules and regulations that apply only to SEC registrants. The FASB issues an Accounting Standards Update ("ASU") to communicate changes to the Codification. We consider the applicability and impact of all ASUs. Recently issued ASUs that are not listed within this Form 10-Q have been assessed and determined to be either not applicable or are not expected to have a material impact on the consolidated financial statements. |
Revenues
Revenues | 9 Months Ended |
Sep. 30, 2023 | |
Revenue from Contract with Customer [Abstract] | |
Revenues | Revenues Disaggregation of Revenue The following table presents our Net sales disaggregated by reportable segment and product line. Three Months Ended September 30, Nine Months Ended September 30, In millions 2023 2022 2023 2022 Performance Materials segment $ 147.2 $ 144.9 $ 433.2 $ 415.7 Performance Chemicals segment $ 256.0 $ 267.6 $ 725.6 $ 683.9 Pavement Technologies product line 129.7 88.3 316.4 194.0 Industrial Specialties product line 126.3 179.3 409.2 489.9 Advanced Polymer Technologies segment $ 42.8 $ 69.5 $ 161.6 $ 185.1 Net sales $ 446.0 $ 482.0 $ 1,320.4 $ 1,284.7 The following table presents our Net sales disaggregated by geography, based on the delivery address of our customer. Three Months Ended September 30, Nine Months Ended September 30, In millions 2023 2022 2023 2022 North America $ 292.4 $ 291.9 $ 854.3 $ 759.7 Asia Pacific 92.4 113.6 264.3 297.3 Europe, Middle East, and Africa 48.6 62.6 167.6 194.0 South America 12.6 13.9 34.2 33.7 Net sales $ 446.0 $ 482.0 $ 1,320.4 $ 1,284.7 Contract Balances The following table provides information about contract assets and contract liabilities from contracts with customers. The contract assets primarily relate to our rights to consideration for products produced but not billed at the reporting date. The contract assets are recognized as accounts receivables when the rights become unconditional and the customer has been billed. Contract liabilities represent obligations to transfer goods to a customer for which we have received consideration from our customer. For all periods presented, we had no contract liabilities. Contract Asset September 30, In millions 2023 2022 Beginning balance $ 6.4 $ 5.3 Contract asset additions 13.2 14.3 Reclassification to accounts receivable, billed to customers (11.7) (13.4) Ending balance (1) $ 7.9 $ 6.2 ______________ (1) Included within "Prepaid and other current assets" on the condensed consolidated balance sheets. |
Fair Value Measurements
Fair Value Measurements | 9 Months Ended |
Sep. 30, 2023 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | Fair Value Measurements Fair Value Measurements Recurring Fair Value Measurements The following information is presented for assets and liabilities that are recorded in the condensed consolidated balance sheets at fair value measured on a recurring basis. There were no transfers of assets and liabilities that were recorded at fair value between the three-level fair value hierarchy during the periods reported. In millions Level 1 (1) Level 2 (2) Level 3 (3) Total September 30, 2023 Assets: Deferred compensation plan investments (4) $ 2.4 $ — $ — $ 2.4 Total assets $ 2.4 $ — $ — $ 2.4 Liabilities: Deferred compensation arrangement (4) $ 15.1 $ — $ — $ 15.1 Total liabilities $ 15.1 $ — $ — $ 15.1 December 31, 2022 Assets: Deferred compensation plan investments (4) $ 1.1 $ — $ — $ 1.1 Total assets $ 1.1 $ — $ — $ 1.1 Liabilities: Deferred compensation arrangement (4) $ 12.5 $ — $ — $ 12.5 Total liabilities $ 12.5 $ — $ — $ 12.5 ______________ (1) Quoted prices in active markets for identical assets. (2) Quoted prices for similar assets and liabilities in active markets. (3) Significant unobservable inputs. (4) Consists of a deferred compensation arrangement, through which we hold various investment securities. Both the asset and liability are recorded at fair value, and are included within "Other assets" and "Other liabilities" on the condensed consolidated balance sheets, respectively. In addition to the investment securities, we also have company-owned life insurance ("COLI") related to the deferred compensation arrangement. COLI is recorded at cash surrender value and included in "Other assets" on the condensed consolidated balance sheets in the amount of $13.8 million and $13.3 million at September 30, 2023 and December 31, 2022, respectively. Nonrecurring Fair Value Measurements There were no nonrecurring fair value measurements in the condensed consolidated balance sheet during the quarters ended September 30, 2023, and December 31, 2022. Strategic Investments Equity Method Investments The aggregate carrying value of all strategic equity method investments totaled $16.1 million and $28.2 million at September 30, 2023 and December 31, 2022, respectively. During the first quarter of 2023, we sold a strategic equity method investment for $31.5 million, resulting in a $19.3 million gain, recorded within "Other (income) expense, net" on the condensed consolidated statement of operations. There were no adjustments to the carrying value of equity method investments for impairment for the periods ended September 30, 2023 and December 31, 2022. Measurement Alternative Investments The aggregate carrying value of all measurement alternative investments where fair value is not readily determinable totaled $83.2 million and $80.8 million at September 30, 2023 and December 31, 2022, respectively. There were no adjustments to the carrying value of the measurement alternative method investments for impairment or observable price changes for the periods ended September 30, 2023 and December 31, 2022. Restricted Investment At September 30, 2023 and December 31, 2022, the carrying value of our restricted investment, which is accounted for as held-to-maturity ("HTM") and therefore recorded at amortized costs, was $80.2 million and $78.0 million, net of an allowance for credit losses of $0.3 million and $0.6 million, and included cash of $9.1 million and $7.0 million, respectively. The fair value at September 30, 2023 and December 31, 2022 was $76.4 million and $74.7 million, respectively, based on Level 1 inputs. The following table shows the total amortized cost of our HTM debt securities by credit rating, excluding the allowance for credit losses and cash. The primary factor in our expected credit loss calculation is the composite bond rating. As the rating decreases, the risk present in holding the bond is inherently increased, leading to an increase in expected credit losses. HTM Debt Securities In millions AA+ AA AA- A A- BBB+ Total September 30, 2023 $ 13.3 — 10.4 13.2 24.4 10.1 $ 71.4 December 31, 2022 $ 13.4 — 10.5 13.2 14.1 20.4 $ 71.6 Debt and Finance Lease Obligations At September 30, 2023 and December 31, 2022, the carrying value of finance lease obligations was $101.3 million and $101.9 million, respectively, and the fair value was $103.6 million and $106.2 million, respectively. The fair value of our finance lease obligation associated with our Performance Materials' Wickliffe, Kentucky, manufacturing site is based on the period-end quoted market prices for the obligations, using Level 2 inputs. The fair value of all other finance lease obligations approximates their carrying values. The carrying amount, excluding debt issuance fees, of our variable interest rate long-term debt was $825.0 million and $828.0 million as of September 30, 2023 and December 31, 2022, respectively. The carrying value is a reasonable estimate of the fair value of the outstanding debt based on the variable interest rate of the debt. |
Inventories, net
Inventories, net | 9 Months Ended |
Sep. 30, 2023 | |
Inventory Disclosure [Abstract] | |
Inventories, net | Inventories, net In millions September 30, 2023 December 31, 2022 Raw materials $ 172.9 $ 106.7 Production materials, stores, and supplies 29.9 27.9 Finished and in-process goods 274.3 228.2 Subtotal $ 477.1 $ 362.8 Less: LIFO reserve (1) (90.4) (27.8) Inventories, net $ 386.7 $ 335.0 |
Property, Plant and Equipment,
Property, Plant and Equipment, net | 9 Months Ended |
Sep. 30, 2023 | |
Property, Plant and Equipment [Abstract] | |
Property, Plant and Equipment, net | Property, Plant, and Equipment, net In millions September 30, 2023 December 31, 2022 Machinery and equipment $ 1,218.1 $ 1,162.7 Buildings and leasehold improvements 210.5 200.9 Land and land improvements 26.3 24.9 Construction in progress 110.9 120.9 Total cost $ 1,565.8 $ 1,509.4 Less: accumulated depreciation (765.8) (710.8) Property, plant, and equipment, net $ 800.0 $ 798.6 |
Goodwill and Other Intangible A
Goodwill and Other Intangible Assets, net | 9 Months Ended |
Sep. 30, 2023 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Goodwill and Other Intangible Assets, net | Goodwill and Other Intangible Assets, net Goodwill As described in Note 1, we reorganized our segment reporting structure to increase transparency for our investors and better align with the markets and customers we serve through each of our segments. This structure is also consistent with the manner in which information is presently used internally by our chief operating decision maker to evaluate performance and make resource allocation decisions. This reportable segment change impacted the identification of our Performance Chemicals reporting unit, resulting in two reporting units, Performance Chemicals and Advanced Polymer Technologies. We have reallocated goodwill as of January 1, 2023 to align to our new reporting unit structure by using a relative fair value approach and tested goodwill for impairment immediately before and after the realignment; no impairment was identified. Reporting Units In millions Performance Materials Performance Chemicals Advanced Polymer Technologies Total December 31, 2022 $ 4.3 $ 514.2 $ — $ 518.5 Segment change reallocation — (165.0) 165.0 — Foreign currency translation — — 1.6 1.6 September 30, 2023 $ 4.3 $ 349.2 $ 166.6 $ 520.1 During the third quarter of 2023, continued reduction in demand in industrial end markets has negatively impacted our ability to offset elevated CTO costs through pricing actions within our Performance Chemicals’ reportable segment, particularly in our industrial specialties product line. CTO is essential to our industrial specialties and some of our pavement technologies product lines within our Performance Chemicals reportable segment. As a result, we concluded that a triggering event occurred for our Performance Chemicals’ reporting unit, and we performed an analysis of the reporting unit’s goodwill, intangibles and long-lived assets as of September 1, 2023. Our analysis included significant assumptions such as: revenue growth rate, Earnings before Interest, Taxes, Depreciation and Amortization ("EBITDA") margin, and discount rate which are judgmental and variations in any assumptions could result in materially different calculations of fair value. Based on our analysis, the headroom associated with our Performance Chemicals’ reporting unit, which is defined as the percentage difference between the fair value of a reporting unit and its carrying value, is 19 percent at September 30, 2023. Consequently, we concluded that there was no impairment for the quarter ended September 30, 2023. Other Intangible Assets In millions Customer contracts and relationships Brands (1) Developed Technology Total Gross Asset Value December 31, 2022 $ 388.5 $ 89.2 $ 88.5 $ 566.2 Foreign currency translation 1.4 0.6 0.6 2.6 September 30, 2023 $ 389.9 $ 89.8 $ 89.1 $ 568.8 Accumulated Amortization December 31, 2022 $ (113.8) $ (23.9) $ (23.7) $ (161.4) Amortization (20.0) (4.3) (7.1) (31.4) Foreign currency translation (0.3) — (0.1) (0.4) September 30, 2023 $ (134.1) $ (28.2) $ (30.9) $ (193.2) Other intangibles, net $ 255.8 $ 61.6 $ 58.2 $ 375.6 _______________ (1) Represents trademarks, trade names, and know-how. Intangible assets subject to amortization were attributed to our business segments as follows: In millions September 30, 2023 December 31, 2022 Performance Materials $ 1.5 $ 1.7 Performance Chemicals 180.7 198.0 Advanced Polymer Technologies 193.4 205.1 Other intangibles, net $ 375.6 $ 404.8 Amortization expense related to our intangible assets is included in Selling, general and administrative expenses on the condensed consolidated statement of operations. During the three and nine months ended September 30, 2023, we recognized amortization expense of $10.5 million and $31.4 million, respectively, and during the three and nine months ended September 30, 2022, we recognized amortization expense of $7.9 million and $23.8 million, respectively. The increase in amortization expense in 2023 as compared to 2022 was due to the Ozark Materials, LLC (“OM”), and Ozark Logistics, LLC (“OL” and, together with OM, “Ozark Materials”) acquisition as further described in Note 16. Based on the current carrying values of intangible assets, estimated pre-tax amortization expense for the next five years is as follows: $10.5 million for the remainder of 2023, 2024 - $41.6 million, 2025 - $41.3 million, 2026 - $40.6 million, and 2027 - $40.6 million. The estimated pre-tax amortization expense may fluctuate due to changes in foreign currency exchange rates. |
Financial Instruments and Risk
Financial Instruments and Risk Management | 9 Months Ended |
Sep. 30, 2023 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Financial Instruments and Risk Management | Financial Instruments and Risk Management Net Investment Hedges In the third quarter of 2022, we terminated our fixed-to-fixed cross-currency interest rate swaps, accounted for as net investment hedges. During the three and nine months ended September 30, 2023, we recognized net interest income associated with this financial instrument of zero and zero, respectively, and during the three and nine months ended September 30, 2022, we recognized net interest income associated with this financial instrument of $0.1 million and $2.8 million, respectively. Cash Flow Hedges Foreign Currency Exchange Risk Management As of September 30, 2023, there were $6.0 million open foreign currency derivative contracts. The fair value of the designated foreign currency hedge contracts was a net asset (liability) of $0.1 million and $(0.5) million at September 30, 2023 and December 31, 2022, respectively. Commodity Price Risk Management As of September 30, 2023, we had 0.8 million and 0.1 million mm BTUS (millions of British Thermal Units) in aggregate notional volume of outstanding natural gas commodity swap contracts and zero cost collar option contracts, respectively, designated as cash flow hedges. As of September 30, 2023, open commodity contracts hedge forecasted transactions until May 2024. The fair value of the outstanding designated natural gas commodity hedge contracts as of September 30, 2023 and December 31, 2022, was a net asset (liability) of $(0.8) million and $(1.6) million, respectively. Interest Rate Risk Management During 2022, we had floating-to-fixed interest rate swaps effectively converting a portion of our floating rate debt to a fixed rate. In the second quarter of 2022, we terminated the interest rate swap instruments. Upon termination of the interest rate swap instruments, we reclassified a $1.7 million gain from AOCI into Interest expense, net on the condensed consolidated statement of operations. Effect of Cash Flow and Net Investment Hedge Accounting on AOCI In millions Amount of Gain (Loss) Recognized in AOCI Amount of Gain (Loss) Reclassified from AOCI into Net income Location of Gain (Loss) Reclassified from AOCI in Net income Three Months Ended September 30, 2023 2022 2023 2022 Cash flow hedging derivatives Currency exchange contracts $ 0.1 $ 0.5 $ (0.2) $ 0.8 Net sales Natural gas contracts (0.3) 3.0 (1.2) 2.3 Cost of sales Interest rate swap contracts — — — — Interest expense, net Total $ (0.2) $ 3.5 $ (1.4) $ 3.1 Amount of Gain (Loss) Recognized in AOCI Amount of Gain (Loss) Recognized in Income on Derivative Location of Gain or (Loss) Recognized in Income on Derivative Three Months Ended September 30, 2023 2022 2023 2022 Net investment hedging derivative Currency exchange contracts (1) $ — $ 4.4 $ — $ 0.1 Interest expense, net Total $ — $ 4.4 $ — $ 0.1 In millions Amount of Gain (Loss) Recognized in AOCI Amount of Gain (Loss) Reclassified from AOCI into Net income Location of Gain (Loss) Reclassified from AOCI in Net income Nine Months Ended September 30, 2023 2022 2023 2022 Cash flow hedging derivatives Currency exchange contracts $ — $ 1.8 $ (0.7) $ 1.6 Net sales Natural gas contracts (3.3) 7.4 (2.2) 4.1 Cost of sales Interest rate swap contracts — 5.7 — 1.7 Interest expense, net Total $ (3.3) $ 14.9 $ (2.9) $ 7.4 In millions Amount of Gain (Loss) Recognized in AOCI Amount of Gain (Loss) Recognized in Income on Derivative Location of Gain or (Loss) Recognized in Income on Derivative Nine Months Ended September 30, 2023 2022 2023 2022 Net investment hedging derivative Currency exchange contracts (1) $ — $ 13.9 $ — $ 2.8 Interest expense, net Total $ — $ 13.9 $ — $ 2.8 __________ (1) Reclassifications from AOCI to Net Income were zero for all periods presented. Gains and losses would be reclassified from AOCI to Other (income) expense, net. Within the next twelve months, we expect to reclassify $2.1 million of net gains from AOCI to income, before taxes. Fair Value Measurements The following information is presented for derivative assets and liabilities that are recorded in the condensed consolidated balance sheets at fair value measured on a recurring basis. There were no transfers of assets and liabilities that are recorded at fair value between Level 1 and Level 2 during the periods reported. There were no nonrecurring fair value measurements related to derivative assets and liabilities on the condensed consolidated balance sheets as of September 30, 2023, or December 31, 2022. September 30, 2023 In millions Level 1 (1) Level 2 (2) Level 3 (3) Total Assets: Currency exchange contracts (4) $ — $ 0.5 $ — $ 0.5 Total assets $ — $ 0.5 $ — $ 0.5 Liabilities: Currency exchange contracts (5) $ — $ 0.4 $ — $ 0.4 Natural gas contracts (5) — 0.8 — 0.8 Total liabilities $ — $ 1.2 $ — $ 1.2 December 31, 2022 In millions Level 1 (1) Level 2 (2) Level 3 (3) Total Liabilities: Natural gas contracts (5) $ — $ 1.6 $ — $ 1.6 Currency exchange contracts (5) — 0.5 — 0.5 Total liabilities $ — $ 2.1 $ — $ 2.1 __________ (1) Quoted prices in active markets for identical assets. (2) Quoted prices for similar assets and liabilities in active markets. (3) Significant unobservable inputs. (4) Included within "Prepaid and other current assets" on the condensed consolidated balance sheet. (5) Included within "Accrued expenses" on the condensed consolidated balance sheet. |
Debt including Finance Lease Ob
Debt including Finance Lease Obligations | 9 Months Ended |
Sep. 30, 2023 | |
Debt Disclosure [Abstract] | |
Debt including Finance Lease Obligations | Debt, including Finance Lease Obligations Current and long-term debt including finance lease obligations consisted of the following: In millions, except percentages September 30, 2023 December 31, 2022 Revolving Credit Facility and other lines of credit (1) $ 825.0 $ 828.0 3.88% Senior Notes due 2028 550.0 550.0 Finance lease obligations 101.3 101.9 Other notes payable 2.0 — Total debt including finance lease obligations $ 1,478.3 $ 1,479.9 Less: debt issuance costs 5.6 6.5 Total debt, including finance lease obligations, net of debt issuance costs $ 1,472.7 $ 1,473.4 Less: debt maturing within one year (2) 3.0 0.9 Long-term debt including finance lease obligations $ 1,469.7 $ 1,472.5 ______________ (1) Letters of credit outstanding under the revolving credit facility were $2.3 million and $2.3 million and available funds under the facility were $172.7 million and $169.7 million at September 30, 2023 and December 31, 2022, respectively. (2) Debt maturing within one year is included in "Notes payable and current maturities of long-term debt" on the condensed consolidated balance sheets. Debt Covenants Our Senior Notes indenture contains certain customary covenants (including covenants limiting Ingevity's and its restricted subsidiaries’ ability to grant or permit liens on certain property securing debt, declare or pay dividends, make distributions on or repurchase or redeem capital stock, make investments in unrestricted subsidiaries, engage in sale and lease-back transactions, and engage in a consolidation or merger, or sell, transfer or otherwise dispose of all or substantially all of the assets of Ingevity and our restricted subsidiaries, taken as a whole) and events of default (subject in certain cases to customary exceptions, as well as grace and cure periods). The occurrence of an event of default under the 2028 Senior Notes could result in the acceleration of the notes of such series and could cause a cross-default resulting in the acceleration of other indebtedness of Ingevity and its subsidiaries. We were in compliance with all covenants under the indenture as of September 30, 2023. The credit agreement governing our revolving credit facility contains customary default provisions, including defaults for non-payment, breach of representations and warranties, insolvency, non-compliance with covenants and cross-defaults to other material indebtedness. The occurrence of an uncured event of default under the credit agreement could result in all loans and other obligations becoming immediately due and payable and our revolving credit facility being terminated. The credit agreement also contains certain customary covenants, including financial covenants. The revolving credit facility financial covenants require Ingevity to maintain on a consolidated basis a maximum total net leverage ratio of 4.0 to 1.0 (which may be increased to 4.5 to 1.0 under certain circumstances) and a minimum interest coverage ratio of 3.0 to 1.0. As calculated per the credit agreement, our net leverage for the four consecutive quarters ended September 30, 2023 was 2.5, and our actual interest coverage for the four consecutive quarters ended September 30, 2023 was 6.8. We were in compliance with all covenants under the credit agreement at September 30, 2023. |
Equity
Equity | 9 Months Ended |
Sep. 30, 2023 | |
Equity [Abstract] | |
Equity | Equity The tables below provide a roll forward of equity. Common Stock In millions, shares in thousands Shares Amount Additional paid in capital Retained earnings Accumulated Treasury stock Total Equity Balance at December 31, 2022 43,228 $ 0.4 $ 153.0 $ 1,007.7 $ (46.8) $ (416.0) $ 698.3 Net income (loss) — — — 50.7 — — 50.7 Other comprehensive income (loss) — — — — 8.0 — 8.0 Common stock issued 139 — — — — — — Exercise of stock options, net 41 — 2.2 — — — 2.2 Tax payments related to vested restricted stock units — — — — — (4.5) (4.5) Share repurchase program — — — — — (33.4) (33.4) Share-based compensation plans — — 3.7 — — 0.7 4.4 Balance at March 31, 2023 43,408 $ 0.4 $ 158.9 $ 1,058.4 $ (38.8) $ (453.2) $ 725.7 Net income (loss) — — — 35.5 — — 35.5 Other comprehensive income (loss) — — — — 5.3 — 5.3 Common stock issued 22 — — — — — — Exercise of stock options, net — — — — — — — Tax payments related to vested restricted stock units — — — — — — — Share repurchase program — — — — — (58.7) (58.7) Share-based compensation plans — — 4.7 — — 1.6 6.3 Balance at June 30, 2023 43,430 $ 0.4 $ 163.6 $ 1,093.9 $ (33.5) $ (510.3) $ 714.1 Net income (loss) — — — 25.2 — — 25.2 Other comprehensive income (loss) — — — — (20.4) — (20.4) Common stock issued 13 — — — — — — Exercise of stock options, net — — — — — — — Tax payments related to vested restricted stock units — — — — — (0.2) (0.2) Share repurchase program — — — — — — — Share-based compensation plans — — (1.0) — — 1.0 — Balance at September 30, 2023 43,443 $ 0.4 $ 162.6 $ 1,119.1 $ (53.9) $ (509.5) $ 718.7 Common Stock In millions, shares in thousands Shares Amount Additional paid in capital Retained earnings Accumulated Treasury stock Total Equity Balance at December 31, 2021 43,102 $ 0.4 $ 136.3 $ 796.1 $ 13.1 $ (272.1) $ 673.8 Net income (loss) — — — 60.8 — — 60.8 Other comprehensive income (loss) — — — — (10.1) — (10.1) Common stock issued 42 — — — — — — Exercise of stock options, net 36 — 0.4 — — — 0.4 Tax payments related to vested restricted stock units — — — — — (1.8) (1.8) Share repurchase program — — — — — (40.4) (40.4) Share-based compensation plans — — 2.9 — — 0.5 3.4 Balance at March 31, 2022 43,180 $ 0.4 $ 139.6 $ 856.9 $ 3.0 $ (313.8) $ 686.1 Net income (loss) — — — 59.8 — — 59.8 Other comprehensive income (loss) — — — — (46.7) — (46.7) Common stock issued 18 — — — — — — Exercise of stock options, net 2 — 0.1 — — — 0.1 Tax payments related to vested restricted stock units — — — — — (0.2) (0.2) Share repurchase program — — — — — (49.5) (49.5) Share-based compensation plans — — 3.3 — — 1.4 4.7 Balance at June 30, 2022 43,200 $ 0.4 $ 143.0 $ 916.7 $ (43.7) $ (362.1) $ 654.3 Net income (loss) — — — 75.4 — — 75.4 Other comprehensive income (loss) — — — — (51.6) — (51.6) Common stock issued 8 — — — — (0.2) (0.2) Exercise of stock options, net 5 — 0.3 — — — 0.3 Tax payments related to vested restricted stock units — — — — — — — Share repurchase program — — — — — (49.3) (49.3) Share-based compensation plans — — 4.2 — — 0.8 5.0 Balance at September 30, 2022 43,213 $ 0.4 $ 147.5 $ 992.1 $ (95.3) $ (410.8) $ 633.9 Accumulated other comprehensive income (loss) Three Months Ended September 30, Nine Months Ended September 30, In millions 2023 2022 2023 2022 Foreign currency translation Beginning balance $ (31.3) $ (43.9) $ (45.8) $ 18.4 Net gains (losses) on foreign currency translation (21.4) (55.3) (6.9) (124.9) Gains (losses) on net investment hedges — 4.4 — 13.9 Less: tax provision (benefit) — 1.0 — 3.2 Net gains (losses) on net investment hedges — 3.4 — 10.7 Other comprehensive income (loss), net of tax (21.4) (51.9) (6.9) (114.2) Ending balance $ (52.7) $ (95.8) $ (52.7) $ (95.8) Derivative instruments Beginning balance $ (2.7) $ 3.3 $ (1.4) $ (2.1) Gains (losses) on derivative instruments (0.2) 3.5 (3.3) 14.9 Less: tax provision (benefit) (0.1) 0.8 (0.8) 3.5 Net gains (losses) on derivative instruments (0.1) 2.7 (2.5) 11.4 (Gains) losses reclassified to net income 1.4 (3.1) 2.9 (7.4) Less: tax (provision) benefit 0.3 (0.7) 0.7 (1.7) Net (gains) losses reclassified to net income 1.1 (2.4) 2.2 (5.7) Other comprehensive income (loss), net of tax 1.0 0.3 (0.3) 5.7 Ending balance $ (1.7) $ 3.6 $ (1.7) $ 3.6 Pension and other postretirement benefits Beginning balance $ 0.5 $ (3.1) $ 0.4 $ (3.2) Unrealized actuarial gains (losses) and prior service (costs) credits — — — — Less: tax provision (benefit) — — — — Net actuarial gains (losses) and prior service (costs) credits — — — — Amortization of actuarial and other (gains) losses, prior service cost (credits), and settlement and curtailment (income) charge reclassified to net income — — 0.1 0.1 Less: tax (provision) benefit — — — — Net actuarial and other (gains) losses, amortization of prior service cost (credits), and settlement and curtailment (income) charge reclassified to net income — — 0.1 0.1 Other comprehensive income (loss), net of tax — — 0.1 0.1 Ending balance $ 0.5 $ (3.1) $ 0.5 $ (3.1) Total AOCI ending balance at September 30 $ (53.9) $ (95.3) $ (53.9) $ (95.3) Reclassifications of accumulated other comprehensive income (loss) Three Months Ended September 30, Nine Months Ended September 30, In millions 2023 2022 2023 2022 Derivative instruments Currency exchange contracts (1) $ (0.2) $ 0.8 $ (0.7) $ 1.6 Natural gas contracts (2) (1.2) 2.3 (2.2) 4.1 Net investment hedge contract (3) — — — 1.7 Total before tax (1.4) 3.1 (2.9) 7.4 (Provision) benefit for income taxes 0.3 (0.7) 0.7 (1.7) Amount included in net income (loss) $ (1.1) $ 2.4 $ (2.2) $ 5.7 Pension and other post retirement benefits Amortization of prior service costs (2) $ — $ — $ 0.1 $ 0.1 Total before tax — — 0.1 0.1 (Provision) benefit for income taxes — — — — Amount included in net income (loss) $ — $ — $ 0.1 $ 0.1 ______________ (1) Included within "Net sales" on the condensed consolidated statement of operations. (2) Included within "Cost of sales" on the condensed consolidated statement of operations. (3) Included within "Interest expense, net" on the condensed consolidated statement of operations. Share Repurchases On July 25, 2022, our Board of Directors authorized the repurchase of up to $500 million of our common stock, and rescinded the prior outstanding repurchase authorization with respect to the shares that remained unused under the prior authorization. Shares may be purchased through open market or privately negotiated transactions at the discretion of management based on its evaluation of market prevailing conditions and other factors, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. During the three and nine months ended September 30, 2023, we repurchased zero and $92.1 million, inclusive of $0.8 million in excise tax, in common stock, representing zero and 1,269,373 shares of our common stock at a weighted average cost per share of zero and $71.93, respectively. At September 30, 2023, $353.4 million remained unused under our Board-authorized repurchase program. |
Restructuring and Other (Income
Restructuring and Other (Income) Charges, net | 9 Months Ended |
Sep. 30, 2023 | |
Restructuring and Related Activities [Abstract] | |
Restructuring and Other (Income) Charges, net | Restructuring and Other (Income) Charges, net Detail on the restructuring charges and other (income) charges, net, is provided below. Three Months Ended September 30, Nine Months Ended September 30, In millions 2023 2022 2023 2022 Severance and other employee-related costs (1) $ 1.5 $ — $ 8.9 $ — Other (2) — — 2.7 — Restructuring charges 1.5 — 11.6 — Alternative Feedstock Transition 11.8 — 18.4 — North Charleston Plant Transition 9.8 — 12.7 — Business transformation costs 1.5 3.3 6.7 10.6 Other (income) charges, net 23.1 3.3 37.8 10.6 Total restructuring and other (income) charges, net $ 24.6 $ 3.3 $ 49.4 $ 10.6 _______________ (1) Represents severance and employee benefit charges. (2) Primarily represents other miscellaneous exit costs. Restructuring Charges Beginning in the first quarter of 2023, we initiated several measures to pursue greater cost efficiency which included a reorganization to streamline certain functions and reduce ongoing costs. During the second and third quarters, we expanded our cost reduction actions to reorganize our operations and in the fourth quarter we announced further actions as described in Note 17. The combined restructuring program is expected to cost approximately $12-14 million and is expected to be completed over the remainder of 2023. During the three and nine months ended September 30, 2023, we recorded $1.5 million and $8.9 million in severance and other employee-related costs and zero and $2.7 million in other restructuring charges, including asset write-offs associated with our reorganization, respectively. Restructuring Reserves Restructuring reserves which are included within Accrued expenses on the condensed consolidated balance sheets were $3.2 million and $0.5 million at September 30, 2023 and December 31, 2022, respectively. Other (income) charges, net Alternative Fatty Acid Transition In April 2023, we began the feedstock transition of our Crossett, Arkansas manufacturing plant (“Crossett”). This transition will convert Crossett from a CTO based feedstock production facility to produce fatty acids from alternative plant based feedstocks. To initiate this transition, we halted all production at Crossett in April. During the three and nine months ended September 30, 2023, we incurred $11.8 million and $18.4 million in costs, respectively. We expect to incur approximately $20-25 million of expense in 2023, representing non-capital retooling and stranded costs, with modest levels of capital expenditure. North Charleston Plant Transition Our North Charleston, South Carolina Performance Chemicals manufacturing plant is co-located with a WestRock Company (“WestRock”) paper mill. WestRock provides certain critical operating services to us including steam, water and wastewater. WestRock also disposes of brine, a by-product resulting from our conversion of black liquor soap skimmings into CTO and provides other non-critical services that support our operations. In May 2023, WestRock announced that it will permanently cease operating its North Charleston paper mill by August 31, 2023 and notified us that it is terminating the shared services in accordance with our operating agreement. We expect to incur approximately $15-20 million of non-capital transition costs in 2023 as we continue to transition those shared services and minimize disruption to our operations and are continuing to evaluate the future impact. During the three and nine months ended September 30, 2023, we incurred $9.8 million and $12.7 million in costs, respectively. Business transformation costs We embarked upon a business transformation initiative that includes the implementation of an upgraded enterprise resource planning ("ERP") system. The implementation of our new ERP occurred in multiple phases beginning with our pilot deployment which occurred during the first quarter of 2022 and concluded with our final deployment in the first quarter of 2023. Costs incurred, during the three and nine months ended September 30, 2023, totaled $1.5 million and $6.7 million, respectively, and during the three and nine months ended September 30, 2022, totaled $3.3 million and $10.6 million, respectively. Costs are directly associated with the business transformation initiative that, in accordance with GAAP, cannot be capitalized. We expect to complete this initiative by the end of 2023 and anticipate incurring an additional $1-2 million in non-capitalizable costs. |
Income Taxes
Income Taxes | 9 Months Ended |
Sep. 30, 2023 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income Taxes The effective tax rates, including discrete items, were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Effective tax rate 21.5 % 21.3 % 22.6 % 21.6 % We determine our interim tax provision using an Estimated Annual Effective Tax Rate methodology (“EAETR”). The EAETR is applied to the year-to-date ordinary income, exclusive of discrete items. The tax effects of discrete items are then included to arrive at the total reported interim tax provision. The determination of the EAETR is based upon a number of estimates, including the estimated annual pre-tax ordinary income in each tax jurisdiction in which we operate. As our projections of ordinary income change throughout the year, the EAETR will change period-to-period. The tax effects of discrete items are recognized in the tax provision in the period they occur. Depending on various factors, such as the item’s significance in relation to total income and the rate of tax applicable in the jurisdiction to which it relates, discrete items in any quarter may materially impact the reported effective tax rate. As a global enterprise, our tax expense may be impacted by changes in tax rates or laws, the finalization of tax audits and reviews, as well as other factors. As such, there may be significant volatility in interim tax provisions. The below table provides a reconciliation between our reported effective tax rates and the EAETR. Three Months Ended September 30, 2023 2022 In millions, except percentages Before tax Tax Effective tax rate % impact Before tax Tax Effective tax rate % impact Consolidated operations $ 32.1 $ 6.9 21.5 % $ 95.8 $ 20.4 21.3 % Discrete items: Restructuring and other (income) charges, net (1) 1.5 0.4 — — Sale of strategic investment (2) (0.1) — — — Other tax only discrete items — 2.3 — (0.3) Total discrete items 1.4 2.7 — (0.3) Consolidated operations, before discrete items $ 33.5 $ 9.6 $ 95.8 $ 20.1 EAETR (3) 28.7 % 21.0 % Nine Months Ended September 30, 2023 2022 In millions, except percentages Before tax Tax Effective tax rate % impact Before tax Tax Effective tax rate % impact Consolidated operations $ 143.9 $ 32.5 22.6 % $ 249.9 $ 53.9 21.6 % Discrete items: Restructuring and other (income) charges, net (1) 8.9 2.1 — — Sale of strategic investment (2) (19.3) (4.5) — — Other tax only discrete items — 2.8 — (1.1) Total discrete items (10.4) 0.4 — (1.1) Consolidated operations, before discrete items $ 133.5 $ 32.9 $ 249.9 $ 52.8 EAETR (3) 24.6 % 21.1 % _______________ (1) See Note 11 for further information. (2) See Note 4 for further information. (3) Increase in EAETR for three and nine months ended September 30, 2023, as compared to September 30, 2022, is due to an overall change in the mix of forecasted earnings in various tax jurisdictions with varying rates, a significant decrease in the foreign derived intangible income benefit, and the corporate tax rate in the UK increasing from 19% to 25% on April 1, 2023. Furthermore, changes in estimates used in the EAETR during the third quarter of 2023 as compared to the second quarter of 2023 attributed to the increase in the EAETR during the three months ended September 30, 2023. At September 30, 2023 and December 31, 2022, we had deferred tax assets of $10.3 million and $9.2 million, respectively, resulting from certain historical net operating losses from our Brazil and China operations and U.S. state tax credits for which a valuation allowance has been established. The ultimate realization of these deferred tax assets depends on the generation of future taxable income during the periods in which these net operating losses and tax credits are available to be used. In evaluating the realizability of these deferred tax assets, we consider projected future taxable income and tax planning strategies in making our assessment. As of September 30, 2023, we cannot objectively assert that these deferred tax assets are more likely than not to be realized and therefore we have maintained a valuation allowance. We intend to continue maintaining a valuation allowance on these deferred tax assets until there is sufficient evidence to support the reversal of all or some portion of these allowances. A release of all or a portion of the valuation allowance could be possible, if we determine that sufficient positive evidence becomes available to allow us to reach a conclusion that the valuation allowance will no longer be needed. A release of the valuation allowance would result in the recognition of certain deferred tax assets and a reduction to income tax expense for the period the release is recorded. However, the exact timing and amount of the valuation allowance release are subject to change based on the level of profitability that we are able to actually achieve. |
Commitments and Contingencies
Commitments and Contingencies | 9 Months Ended |
Sep. 30, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Commitments and Contingencies Legal Proceedings On July 19, 2018, we filed suit against BASF Corporation (“BASF”) in the United States District Court for the District of Delaware (the “Delaware Proceeding”) alleging BASF infringed Ingevity’s patent covering canister systems used in the control of automotive gasoline vapor emissions (U.S. Patent No. RE38,844) (the “844 Patent”). On February 14, 2019, BASF asserted counterclaims against us in the Delaware Proceeding, alleging two claims for violations of U.S. antitrust law (one for exclusive dealing and the other for tying) as well as a claim for tortious interference with an alleged prospective business relationship between BASF and a BASF customer (the “BASF Counterclaims”). The BASF Counterclaims relate to our enforcement of the 844 Patent and our entry into several supply agreements with customers of our fuel vapor canister honeycombs. The U.S. District Court dismissed our patent infringement claims on November 18, 2020, and the case proceeded to trial on the BASF Counterclaims in September 2021. On September 15, 2021, a jury in the Delaware Proceeding issued a verdict in favor of BASF on the BASF Counterclaims and awarded BASF damages of approximately $28.3 million, which trebled under U.S. antitrust law to approximately $85.0 million. On May 18, 2023, the court in the Delaware Proceeding entered judgment on the jury’s verdict, which commenced the post-trial briefing stage. In addition, BASF is seeking pre-judgment interest and has indicated it will seek attorneys’ fees and costs in amounts that they will have to support at a future date. Unless the judgment is set aside, BASF will be entitled to post-judgment interest pursuant to the rate provided under federal law. We disagree with the verdict, including the court’s application of the law and entry of judgment, and are seeking judgment as a matter of law, or a new trial in the alternative, in the Delaware Proceeding post-trial briefing stage and intend to do so on appeal, if necessary. In addition, we may challenge the U.S. District Court’s November 2020 dismissal of our patent infringement claims against BASF. Ingevity believes in the strength of its intellectual property and the merits of its position and intends to pursue all legal relief available to challenge these outcomes in the Delaware Proceeding. Final resolution of these matters could take up to 30 months. As of September 30, 2023, nothing has occurred in the post-trial proceedings to warrant any change to our conclusions as disclosed within our 2022 Annual Report. The full amount of the trebled jury's verdict, $85.0 million, is accrued in Other liabilities on the condensed consolidated balance sheet as of September 30, 2023. In addition, as a result of the judgment being officially entered on May 18, 2023, we have started accruing for the post-judgment interest. The amount of any liability we may ultimately incur could be more or less than the amount accrued. |
Segment Information
Segment Information | 9 Months Ended |
Sep. 30, 2023 | |
Segment Reporting [Abstract] | |
Segment Information | Segment Information Segment change As described in Note 1, effective in the first quarter of 2023, we separated our engineered polymers product line from the Performance Chemicals reportable segment into its own reportable segment, Advanced Polymer Technologies. We have recast the data below to reflect the changes in our reportable segments to conform to the current year presentation. Three Months Ended September 30, Nine Months Ended September 30, In millions 2023 2022 2023 2022 Net sales Performance Materials $ 147.2 $ 144.9 $ 433.2 $ 415.7 Performance Chemicals 256.0 267.6 725.6 683.9 Advanced Polymer Technologies 42.8 69.5 161.6 185.1 Total net sales (1) $ 446.0 $ 482.0 $ 1,320.4 $ 1,284.7 Segment EBITDA (2) Performance Materials $ 74.5 $ 61.2 $ 208.5 $ 194.7 Performance Chemicals 24.7 65.7 89.9 158.2 Advanced Polymer Technologies 11.2 11.3 36.6 25.4 Total Segment EBITDA (2) $ 110.4 $ 138.2 $ 335.0 $ 378.3 Interest expense, net (23.1) (11.5) (64.3) (37.3) (Provision) benefit for income taxes (6.9) (20.4) (32.5) (53.9) Depreciation and amortization - Performance Materials (9.5) (8.9) (28.7) (26.7) Depreciation and amortization - Performance Chemicals (17.8) (9.7) (45.6) (29.4) Depreciation and amortization - Advanced Polymer Technologies (7.9) (7.1) (23.4) (22.5) Restructuring and other income (charges), net (3), (6) (20.0) (3.3) (43.8) (10.6) Acquisition and other-related costs (4) (0.1) (1.9) (4.6) (1.9) Gain on sale of strategic investment (5) 0.1 — 19.3 — Net income (loss) $ 25.2 $ 75.4 $ 111.4 $ 196.0 _______________ (1) Relates to external customers only, all intersegment sales and related profit have been eliminated in consolidation. (2) Segment EBITDA is the primary measure used by our chief operating decision maker to evaluate the performance of and allocate resources among our operating segments. Segment EBITDA is defined as segment revenue less segment operating expenses (segment operating expenses consist of costs of sales, selling, general and administrative expenses, research and technical expenses, other (income) expense, net, excluding depreciation and amortization). We have excluded the following items from segment EBITDA: interest expense, net, associated with corporate debt facilities, income taxes, depreciation, amortization, restructuring and other (income) charges, net, acquisition and other related costs, litigation verdict charges, (losses) and gains from the sale of strategic investments, and pension and postretirement settlement and curtailment (income) charges, net. (3) For the three and nine months ended September 30, 2023, charges of $1.3 million and $7.5 million relate to the Performance Materials segment, charges of $18.3 million and $34.0 million relate to the Performance Chemicals segment, and charges of $0.4 million and $2.3 million relate to the Advanced Polymer Technologies segment, respectively. For the three and nine months ended September 30, 2022, charges of $1.1 million and $3.7 million relate to the Performance Materials segment, charges of $1.7 million and $5.4 million relate to the Performance Chemicals segment, and charges of $0.5 million and $1.5 million relate to the Advanced Polymer Technologies segment, respectively. For more detail on the charges incurred see Note 11. (4) For the three and nine months ended September 30, 2023 and September 30, 2022, all charges relate to the acquisition and integration of Ozark Materials into the Performance Chemicals segment. For more detail see Note 16. (5) For the three and nine months ended September 30, 2023, gain on sale of strategic investment relates to the Performance Materials segment. For more detail see Note 4. |
Earnings (Loss) per Share
Earnings (Loss) per Share | 9 Months Ended |
Sep. 30, 2023 | |
Earnings Per Share [Abstract] | |
Earnings (Loss) per Share | Earnings (Loss) per Share Basic earnings (loss) per share is computed by dividing net income (loss) for the period by the weighted average number of common shares outstanding during the period. Diluted earnings (loss) per share is computed by dividing net income (loss) for the period by the weighted average number of common shares and potentially dilutive common shares outstanding for the period. The calculation of diluted net income per share excludes all antidilutive common shares. Three Months Ended September 30, Nine Months Ended September 30, In millions, except share and per share data 2023 2022 2023 2022 Net income (loss) $ 25.2 $ 75.4 $ 111.4 $ 196.0 Basic and Diluted earnings (loss) per share Basic earnings (loss) per share $ 0.70 $ 1.99 $ 3.05 $ 5.10 Diluted earnings (loss) per share 0.69 1.98 3.03 5.06 Shares (in thousands) Weighted average number of common shares outstanding - Basic 36,225 37,839 36,585 38,451 Weighted average additional shares assuming conversion of potential common shares 162 295 226 269 Shares - diluted basis 36,387 38,134 36,811 38,720 The following average number of potential common shares were antidilutive, and therefore, were not included in the diluted earnings per share calculation: Three Months Ended September 30, Nine Months Ended September 30, In thousands 2023 2022 2023 2022 Average number of potential common shares - antidilutive 491 209 400 204 |
Acquisitions
Acquisitions | 9 Months Ended |
Sep. 30, 2023 | |
Business Combination and Asset Acquisition [Abstract] | |
Acquisitions | Acquisitions Ozark Materials On October 3, 2022, we completed our acquisition of Ozark Materials, pursuant to that certain Equity Purchase Agreement (the “Purchase Agreement”), by and among Ingevity, Ozark Materials and Ozark Holdings, Inc. (“Seller”). In accordance with the Purchase Agreement, we acquired from Seller, all of the issued and outstanding limited liability company membership interests of Ozark Materials for a purchase price of $325.0 million, subject to customary adjustments for working capital, indebtedness and transaction expenses (the "Acquisition"). The Acquisition has been integrated into our Performance Chemicals segment and is included within our pavement technologies product line. We funded the Acquisition through a combination of borrowings under our existing credit facilities and cash on hand. The Acquisition is not considered significant to our condensed consolidated financial statements for the three and nine months ended September 30, 2023; therefore, proforma results of operations have not been presented. Purchase Price Allocation Ozark Materials is considered an acquisition of a business under business combinations accounting guidance, and therefore we applied acquisition accounting. Acquisition accounting requires, among other things, that assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date. The aggregate purchase price noted above was allocated to the major categories of assets acquired and liabilities assumed based upon their estimated fair values at the acquisition date using primarily Level 2 and Level 3 inputs. These Level 2 and Level 3 valuation inputs include an estimate of future cash flows and discount rates. Additionally, estimated fair values are based, in part, upon outside appraisals for certain assets, including specifically-identified intangible assets. See Note 4 for an additional explanation of Level 2 and Level 3 inputs. We finalized the purchase price allocation in the third quarter of 2023. Purchase Price Allocation In millions Weighted Average Amortization Period Fair Value Cash and cash equivalents $ 8.0 Accounts receivable 28.7 Inventories (1) 48.4 Prepaid and other current assets 2.0 Property, plant and equipment 43.1 Intangible assets (2) Brands 10 years 15.0 Customer relationships 15 years 88.6 Developed technology 7 years 23.5 Goodwill (3) 109.8 Other assets, including operating leases 0.1 Total fair value of assets acquired $ 367.2 Accounts payable 13.9 Other liabilities 2.6 Total fair value of liabilities assumed $ 16.5 Less: Cash acquired (8.0) Plus: Amounts due from Seller 1.8 Total cash paid, less cash and restricted cash acquired $ 344.5 _______________ (1) Fair value of finished goods inventories acquired included a step-up in the value of $1.8 million, of which zero and $0.8 million was expensed in the three and nine months ended September 30, 2023. The expense is included within "Cost of sales" on the consolidated statement of operations. Inventories are accounted for on a FIFO basis of accounting. (2) The aggregate amortization expense was $2.7 million and $8.2 million for the three and nine months ended September 30, 2023. Estimated amortization expense is as follows: $2.7 million for the remainder of 2023, 2024 - $10.9 million, 2025 - $10.7 million, 2026 - $10.0 million, and 2027 - $10.0 million. (3) Goodwill largely consists of expected cost synergies and economies of scale resulting from the business combination. We expect the full amount to be deductible for income tax purposes. This acquired goodwill has been included within our Performance Chemicals reporting unit. See Note 7 for further information regarding our allocation of goodwill among our reporting units. Acquisition and other-related costs Costs incurred to complete and integrate acquisitions and other strategic investments are expensed as incurred on our consolidated statement of operations. The following table summarizes the costs incurred associated with these combined activities. Three Months Ended September 30, Nine Months Ended September 30, In millions 2023 2022 2023 2022 Legal and professional service fees $ 0.1 $ 1.9 $ 3.8 $ 1.9 Acquisition-related costs 0.1 1.9 3.8 1.9 Inventory fair value step-up amortization (1) — — 0.8 — Acquisition and other-related costs $ 0.1 $ 1.9 $ 4.6 $ 1.9 _______________ (1) Included within "Cost of sales" on the consolidated statement of operations. |
Subsequent Events
Subsequent Events | 9 Months Ended |
Sep. 30, 2023 | |
Subsequent Events [Abstract] | |
Subsequent Events | Subsequent Events On November 1, 2023, we announced a number of strategic actions designed to further reposition our Performance Chemicals segment to improve the profitability and reduce the cyclicality of the Performance Chemicals business and the Company as a whole. These actions increase our focus on growing our most profitable Performance Chemicals product lines such as Pavement Technologies and accelerate our transition to non-CTO-based fatty acids. The announced actions include the permanent closure of our Performance Chemicals manufacturing plant located in DeRidder, Louisiana (the “DeRidder Plant”) as well as additional corporate and business cost reduction actions. We expect to close the DeRidder Plant by the end of the first half of 2024. We expect to incur aggregate charges of approximately $280.0 million associated with these actions, consisting of approximately $180.0 million in asset-related charges, approximately $15.0 million in severance and other employee-related costs, and approximately $85.0 million in other restructuring costs including decommissioning, dismantling and removal charges, and contract termination costs. We expect approximately $180.0 million of the total charges to be non-cash. The majority of non-cash charges and 50-60 percent of cash charges are expected to be recognized by the end of the first half of 2024. Excluded from the $280.0 million of estimated aggregate charges are potential costs we may incur associated with excess volumes of CTO that we may be obligated to purchase through October 2025 under existing long-term CTO supply contracts. We intend to manage our CTO inventories by reselling excess volumes in the open market which, based on what we believe to be market rates today, may result in $30.0 million to $80.0 million of incremental losses in 2024. The charges we currently expect to incur in connection with these actions are subject to a number of assumptions and risks, and actual results may differ materially. We may also incur other material charges not currently contemplated due to events that may occur as a result of, or in connection with, these actions. |
New Accounting Guidance (Polici
New Accounting Guidance (Policies) | 9 Months Ended |
Sep. 30, 2023 | |
Accounting Policies [Abstract] | |
Basis of Consolidation | Basis of Consolidation and Presentation These unaudited Condensed Consolidated Financial Statements reflect the consolidated operations of the Company and have been prepared in accordance with United States Securities and Exchange Commission ("SEC") interim reporting requirements. Accordingly, the accompanying Condensed Consolidated Financial Statements do not include all disclosures required by accounting principles generally accepted in the United States of America ("GAAP") for full financial statements and should be read in conjunction with the Annual Consolidated Financial Statements for the years ended December 31, 2022, 2021 and 2020, collectively referred to as the “Annual Consolidated Financial Statements,” included in our Annual Report on Form 10-K for the year ended December 31, 2022 (the "2022 Annual Report"). In the opinion of management, the Condensed Consolidated Financial Statements contain all adjustments which include only normal recurring adjustments necessary to fairly state the condensed consolidated results for the interim periods presented. The consolidated results of operations for interim periods are not necessarily indicative of the results to be expected for the full year. The preparation of the Condensed Consolidated Financial Statements requires management to make estimates and assumptions with respect to the reported amounts of assets, liabilities, revenue, and expenses and the disclosure of contingent assets and liabilities. Actual results could differ from these estimates. Certain prior year amounts have been reclassified to conform with the current year's presentation. |
Basis of Presentation | Basis of Consolidation and Presentation These unaudited Condensed Consolidated Financial Statements reflect the consolidated operations of the Company and have been prepared in accordance with United States Securities and Exchange Commission ("SEC") interim reporting requirements. Accordingly, the accompanying Condensed Consolidated Financial Statements do not include all disclosures required by accounting principles generally accepted in the United States of America ("GAAP") for full financial statements and should be read in conjunction with the Annual Consolidated Financial Statements for the years ended December 31, 2022, 2021 and 2020, collectively referred to as the “Annual Consolidated Financial Statements,” included in our Annual Report on Form 10-K for the year ended December 31, 2022 (the "2022 Annual Report"). In the opinion of management, the Condensed Consolidated Financial Statements contain all adjustments which include only normal recurring adjustments necessary to fairly state the condensed consolidated results for the interim periods presented. The consolidated results of operations for interim periods are not necessarily indicative of the results to be expected for the full year. The preparation of the Condensed Consolidated Financial Statements requires management to make estimates and assumptions with respect to the reported amounts of assets, liabilities, revenue, and expenses and the disclosure of contingent assets and liabilities. Actual results could differ from these estimates. Certain prior year amounts have been reclassified to conform with the current year's presentation. |
Recently Issued Accounting Pronouncements | New Accounting GuidanceThe Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC" or "Codification") is the sole source of authoritative GAAP other than SEC issued rules and regulations that apply only to SEC registrants. The FASB issues an Accounting Standards Update ("ASU") to communicate changes to the Codification. We consider the applicability and impact of all ASUs. Recently issued ASUs that are not listed within this Form 10-Q have been assessed and determined to be either not applicable or are not expected to have a material impact on the consolidated financial statements. |
Income tax | We determine our interim tax provision using an Estimated Annual Effective Tax Rate methodology (“EAETR”). The EAETR is applied to the year-to-date ordinary income, exclusive of discrete items. The tax effects of discrete items are then included to arrive at the total reported interim tax provision. The determination of the EAETR is based upon a number of estimates, including the estimated annual pre-tax ordinary income in each tax jurisdiction in which we operate. As our projections of ordinary income change throughout the year, the EAETR will change period-to-period. The tax effects of discrete items are recognized in the tax provision in the period they occur. Depending on various factors, such as the item’s significance in relation to total income and the rate of tax applicable in the jurisdiction to which it relates, discrete items in any quarter may materially impact the reported effective tax rate. As a global enterprise, our tax expense may be impacted by changes in tax rates or laws, the finalization of tax audits and reviews, as well as other factors. As such, there may be significant volatility in interim tax provisions. |
Revenues (Tables)
Revenues (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Revenue from Contract with Customer [Abstract] | |
Schedule of Disaggregation of Revenue | The following table presents our Net sales disaggregated by reportable segment and product line. Three Months Ended September 30, Nine Months Ended September 30, In millions 2023 2022 2023 2022 Performance Materials segment $ 147.2 $ 144.9 $ 433.2 $ 415.7 Performance Chemicals segment $ 256.0 $ 267.6 $ 725.6 $ 683.9 Pavement Technologies product line 129.7 88.3 316.4 194.0 Industrial Specialties product line 126.3 179.3 409.2 489.9 Advanced Polymer Technologies segment $ 42.8 $ 69.5 $ 161.6 $ 185.1 Net sales $ 446.0 $ 482.0 $ 1,320.4 $ 1,284.7 The following table presents our Net sales disaggregated by geography, based on the delivery address of our customer. Three Months Ended September 30, Nine Months Ended September 30, In millions 2023 2022 2023 2022 North America $ 292.4 $ 291.9 $ 854.3 $ 759.7 Asia Pacific 92.4 113.6 264.3 297.3 Europe, Middle East, and Africa 48.6 62.6 167.6 194.0 South America 12.6 13.9 34.2 33.7 Net sales $ 446.0 $ 482.0 $ 1,320.4 $ 1,284.7 |
Schedule of Contract with Customer, Asset and Liability | The following table provides information about contract assets and contract liabilities from contracts with customers. The contract assets primarily relate to our rights to consideration for products produced but not billed at the reporting date. The contract assets are recognized as accounts receivables when the rights become unconditional and the customer has been billed. Contract liabilities represent obligations to transfer goods to a customer for which we have received consideration from our customer. For all periods presented, we had no contract liabilities. Contract Asset September 30, In millions 2023 2022 Beginning balance $ 6.4 $ 5.3 Contract asset additions 13.2 14.3 Reclassification to accounts receivable, billed to customers (11.7) (13.4) Ending balance (1) $ 7.9 $ 6.2 ______________ (1) Included within "Prepaid and other current assets" on the condensed consolidated balance sheets. |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Fair Value Disclosures [Abstract] | |
Schedule of Fair Value Measurements, Recurring | The following information is presented for assets and liabilities that are recorded in the condensed consolidated balance sheets at fair value measured on a recurring basis. There were no transfers of assets and liabilities that were recorded at fair value between the three-level fair value hierarchy during the periods reported. In millions Level 1 (1) Level 2 (2) Level 3 (3) Total September 30, 2023 Assets: Deferred compensation plan investments (4) $ 2.4 $ — $ — $ 2.4 Total assets $ 2.4 $ — $ — $ 2.4 Liabilities: Deferred compensation arrangement (4) $ 15.1 $ — $ — $ 15.1 Total liabilities $ 15.1 $ — $ — $ 15.1 December 31, 2022 Assets: Deferred compensation plan investments (4) $ 1.1 $ — $ — $ 1.1 Total assets $ 1.1 $ — $ — $ 1.1 Liabilities: Deferred compensation arrangement (4) $ 12.5 $ — $ — $ 12.5 Total liabilities $ 12.5 $ — $ — $ 12.5 ______________ (1) Quoted prices in active markets for identical assets. (2) Quoted prices for similar assets and liabilities in active markets. (3) Significant unobservable inputs. (4) Consists of a deferred compensation arrangement, through which we hold various investment securities. Both the asset and liability are recorded at fair value, and are included within "Other assets" and "Other liabilities" on the condensed consolidated balance sheets, respectively. In addition to the investment securities, we also have company-owned life insurance ("COLI") related to the deferred compensation arrangement. COLI is recorded at cash surrender value and included in "Other assets" on the condensed consolidated balance sheets in the amount of $13.8 million and $13.3 million at September 30, 2023 and December 31, 2022, respectively. |
Schedule of Debt Securities, Held-to-maturity, Credit Quality Indicator | The following table shows the total amortized cost of our HTM debt securities by credit rating, excluding the allowance for credit losses and cash. The primary factor in our expected credit loss calculation is the composite bond rating. As the rating decreases, the risk present in holding the bond is inherently increased, leading to an increase in expected credit losses. HTM Debt Securities In millions AA+ AA AA- A A- BBB+ Total September 30, 2023 $ 13.3 — 10.4 13.2 24.4 10.1 $ 71.4 December 31, 2022 $ 13.4 — 10.5 13.2 14.1 20.4 $ 71.6 |
Inventories, net (Tables)
Inventories, net (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Inventory Disclosure [Abstract] | |
Schedule of Inventory | In millions September 30, 2023 December 31, 2022 Raw materials $ 172.9 $ 106.7 Production materials, stores, and supplies 29.9 27.9 Finished and in-process goods 274.3 228.2 Subtotal $ 477.1 $ 362.8 Less: LIFO reserve (1) (90.4) (27.8) Inventories, net $ 386.7 $ 335.0 |
Property, Plant and Equipment_2
Property, Plant and Equipment, net (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Property, Plant and Equipment [Abstract] | |
Schedule of Property, Plant and Equipment | In millions September 30, 2023 December 31, 2022 Machinery and equipment $ 1,218.1 $ 1,162.7 Buildings and leasehold improvements 210.5 200.9 Land and land improvements 26.3 24.9 Construction in progress 110.9 120.9 Total cost $ 1,565.8 $ 1,509.4 Less: accumulated depreciation (765.8) (710.8) Property, plant, and equipment, net $ 800.0 $ 798.6 |
Goodwill and Other Intangible_2
Goodwill and Other Intangible Assets, net (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of Goodwill | Reporting Units In millions Performance Materials Performance Chemicals Advanced Polymer Technologies Total December 31, 2022 $ 4.3 $ 514.2 $ — $ 518.5 Segment change reallocation — (165.0) 165.0 — Foreign currency translation — — 1.6 1.6 September 30, 2023 $ 4.3 $ 349.2 $ 166.6 $ 520.1 |
Schedule of Finite-Lived Intangible Assets | In millions Customer contracts and relationships Brands (1) Developed Technology Total Gross Asset Value December 31, 2022 $ 388.5 $ 89.2 $ 88.5 $ 566.2 Foreign currency translation 1.4 0.6 0.6 2.6 September 30, 2023 $ 389.9 $ 89.8 $ 89.1 $ 568.8 Accumulated Amortization December 31, 2022 $ (113.8) $ (23.9) $ (23.7) $ (161.4) Amortization (20.0) (4.3) (7.1) (31.4) Foreign currency translation (0.3) — (0.1) (0.4) September 30, 2023 $ (134.1) $ (28.2) $ (30.9) $ (193.2) Other intangibles, net $ 255.8 $ 61.6 $ 58.2 $ 375.6 _______________ (1) Represents trademarks, trade names, and know-how. Intangible assets subject to amortization were attributed to our business segments as follows: In millions September 30, 2023 December 31, 2022 Performance Materials $ 1.5 $ 1.7 Performance Chemicals 180.7 198.0 Advanced Polymer Technologies 193.4 205.1 Other intangibles, net $ 375.6 $ 404.8 |
Financial Instruments and Ris_2
Financial Instruments and Risk Management (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Schedule of Effect of Cash Flow and Net Investment Hedge Accounting on Accumulated Other Comprehensive Income | In millions Amount of Gain (Loss) Recognized in AOCI Amount of Gain (Loss) Reclassified from AOCI into Net income Location of Gain (Loss) Reclassified from AOCI in Net income Three Months Ended September 30, 2023 2022 2023 2022 Cash flow hedging derivatives Currency exchange contracts $ 0.1 $ 0.5 $ (0.2) $ 0.8 Net sales Natural gas contracts (0.3) 3.0 (1.2) 2.3 Cost of sales Interest rate swap contracts — — — — Interest expense, net Total $ (0.2) $ 3.5 $ (1.4) $ 3.1 Amount of Gain (Loss) Recognized in AOCI Amount of Gain (Loss) Recognized in Income on Derivative Location of Gain or (Loss) Recognized in Income on Derivative Three Months Ended September 30, 2023 2022 2023 2022 Net investment hedging derivative Currency exchange contracts (1) $ — $ 4.4 $ — $ 0.1 Interest expense, net Total $ — $ 4.4 $ — $ 0.1 In millions Amount of Gain (Loss) Recognized in AOCI Amount of Gain (Loss) Reclassified from AOCI into Net income Location of Gain (Loss) Reclassified from AOCI in Net income Nine Months Ended September 30, 2023 2022 2023 2022 Cash flow hedging derivatives Currency exchange contracts $ — $ 1.8 $ (0.7) $ 1.6 Net sales Natural gas contracts (3.3) 7.4 (2.2) 4.1 Cost of sales Interest rate swap contracts — 5.7 — 1.7 Interest expense, net Total $ (3.3) $ 14.9 $ (2.9) $ 7.4 In millions Amount of Gain (Loss) Recognized in AOCI Amount of Gain (Loss) Recognized in Income on Derivative Location of Gain or (Loss) Recognized in Income on Derivative Nine Months Ended September 30, 2023 2022 2023 2022 Net investment hedging derivative Currency exchange contracts (1) $ — $ 13.9 $ — $ 2.8 Interest expense, net Total $ — $ 13.9 $ — $ 2.8 __________ |
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value | The following information is presented for derivative assets and liabilities that are recorded in the condensed consolidated balance sheets at fair value measured on a recurring basis. There were no transfers of assets and liabilities that are recorded at fair value between Level 1 and Level 2 during the periods reported. There were no nonrecurring fair value measurements related to derivative assets and liabilities on the condensed consolidated balance sheets as of September 30, 2023, or December 31, 2022. September 30, 2023 In millions Level 1 (1) Level 2 (2) Level 3 (3) Total Assets: Currency exchange contracts (4) $ — $ 0.5 $ — $ 0.5 Total assets $ — $ 0.5 $ — $ 0.5 Liabilities: Currency exchange contracts (5) $ — $ 0.4 $ — $ 0.4 Natural gas contracts (5) — 0.8 — 0.8 Total liabilities $ — $ 1.2 $ — $ 1.2 December 31, 2022 In millions Level 1 (1) Level 2 (2) Level 3 (3) Total Liabilities: Natural gas contracts (5) $ — $ 1.6 $ — $ 1.6 Currency exchange contracts (5) — 0.5 — 0.5 Total liabilities $ — $ 2.1 $ — $ 2.1 __________ (1) Quoted prices in active markets for identical assets. (2) Quoted prices for similar assets and liabilities in active markets. (3) Significant unobservable inputs. (4) Included within "Prepaid and other current assets" on the condensed consolidated balance sheet. (5) Included within "Accrued expenses" on the condensed consolidated balance sheet. |
Debt including Finance Lease _2
Debt including Finance Lease Obligations (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Debt Disclosure [Abstract] | |
Schedule of Long-term Debt Instruments | Current and long-term debt including finance lease obligations consisted of the following: In millions, except percentages September 30, 2023 December 31, 2022 Revolving Credit Facility and other lines of credit (1) $ 825.0 $ 828.0 3.88% Senior Notes due 2028 550.0 550.0 Finance lease obligations 101.3 101.9 Other notes payable 2.0 — Total debt including finance lease obligations $ 1,478.3 $ 1,479.9 Less: debt issuance costs 5.6 6.5 Total debt, including finance lease obligations, net of debt issuance costs $ 1,472.7 $ 1,473.4 Less: debt maturing within one year (2) 3.0 0.9 Long-term debt including finance lease obligations $ 1,469.7 $ 1,472.5 ______________ (1) Letters of credit outstanding under the revolving credit facility were $2.3 million and $2.3 million and available funds under the facility were $172.7 million and $169.7 million at September 30, 2023 and December 31, 2022, respectively. (2) Debt maturing within one year is included in "Notes payable and current maturities of long-term debt" on the condensed consolidated balance sheets. |
Equity (Tables)
Equity (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Equity [Abstract] | |
Schedule of Stockholders' Equity | The tables below provide a roll forward of equity. Common Stock In millions, shares in thousands Shares Amount Additional paid in capital Retained earnings Accumulated Treasury stock Total Equity Balance at December 31, 2022 43,228 $ 0.4 $ 153.0 $ 1,007.7 $ (46.8) $ (416.0) $ 698.3 Net income (loss) — — — 50.7 — — 50.7 Other comprehensive income (loss) — — — — 8.0 — 8.0 Common stock issued 139 — — — — — — Exercise of stock options, net 41 — 2.2 — — — 2.2 Tax payments related to vested restricted stock units — — — — — (4.5) (4.5) Share repurchase program — — — — — (33.4) (33.4) Share-based compensation plans — — 3.7 — — 0.7 4.4 Balance at March 31, 2023 43,408 $ 0.4 $ 158.9 $ 1,058.4 $ (38.8) $ (453.2) $ 725.7 Net income (loss) — — — 35.5 — — 35.5 Other comprehensive income (loss) — — — — 5.3 — 5.3 Common stock issued 22 — — — — — — Exercise of stock options, net — — — — — — — Tax payments related to vested restricted stock units — — — — — — — Share repurchase program — — — — — (58.7) (58.7) Share-based compensation plans — — 4.7 — — 1.6 6.3 Balance at June 30, 2023 43,430 $ 0.4 $ 163.6 $ 1,093.9 $ (33.5) $ (510.3) $ 714.1 Net income (loss) — — — 25.2 — — 25.2 Other comprehensive income (loss) — — — — (20.4) — (20.4) Common stock issued 13 — — — — — — Exercise of stock options, net — — — — — — — Tax payments related to vested restricted stock units — — — — — (0.2) (0.2) Share repurchase program — — — — — — — Share-based compensation plans — — (1.0) — — 1.0 — Balance at September 30, 2023 43,443 $ 0.4 $ 162.6 $ 1,119.1 $ (53.9) $ (509.5) $ 718.7 Common Stock In millions, shares in thousands Shares Amount Additional paid in capital Retained earnings Accumulated Treasury stock Total Equity Balance at December 31, 2021 43,102 $ 0.4 $ 136.3 $ 796.1 $ 13.1 $ (272.1) $ 673.8 Net income (loss) — — — 60.8 — — 60.8 Other comprehensive income (loss) — — — — (10.1) — (10.1) Common stock issued 42 — — — — — — Exercise of stock options, net 36 — 0.4 — — — 0.4 Tax payments related to vested restricted stock units — — — — — (1.8) (1.8) Share repurchase program — — — — — (40.4) (40.4) Share-based compensation plans — — 2.9 — — 0.5 3.4 Balance at March 31, 2022 43,180 $ 0.4 $ 139.6 $ 856.9 $ 3.0 $ (313.8) $ 686.1 Net income (loss) — — — 59.8 — — 59.8 Other comprehensive income (loss) — — — — (46.7) — (46.7) Common stock issued 18 — — — — — — Exercise of stock options, net 2 — 0.1 — — — 0.1 Tax payments related to vested restricted stock units — — — — — (0.2) (0.2) Share repurchase program — — — — — (49.5) (49.5) Share-based compensation plans — — 3.3 — — 1.4 4.7 Balance at June 30, 2022 43,200 $ 0.4 $ 143.0 $ 916.7 $ (43.7) $ (362.1) $ 654.3 Net income (loss) — — — 75.4 — — 75.4 Other comprehensive income (loss) — — — — (51.6) — (51.6) Common stock issued 8 — — — — (0.2) (0.2) Exercise of stock options, net 5 — 0.3 — — — 0.3 Tax payments related to vested restricted stock units — — — — — — — Share repurchase program — — — — — (49.3) (49.3) Share-based compensation plans — — 4.2 — — 0.8 5.0 Balance at September 30, 2022 43,213 $ 0.4 $ 147.5 $ 992.1 $ (95.3) $ (410.8) $ 633.9 |
Schedule of Accumulated Other Comprehensive Income (Loss) | Accumulated other comprehensive income (loss) Three Months Ended September 30, Nine Months Ended September 30, In millions 2023 2022 2023 2022 Foreign currency translation Beginning balance $ (31.3) $ (43.9) $ (45.8) $ 18.4 Net gains (losses) on foreign currency translation (21.4) (55.3) (6.9) (124.9) Gains (losses) on net investment hedges — 4.4 — 13.9 Less: tax provision (benefit) — 1.0 — 3.2 Net gains (losses) on net investment hedges — 3.4 — 10.7 Other comprehensive income (loss), net of tax (21.4) (51.9) (6.9) (114.2) Ending balance $ (52.7) $ (95.8) $ (52.7) $ (95.8) Derivative instruments Beginning balance $ (2.7) $ 3.3 $ (1.4) $ (2.1) Gains (losses) on derivative instruments (0.2) 3.5 (3.3) 14.9 Less: tax provision (benefit) (0.1) 0.8 (0.8) 3.5 Net gains (losses) on derivative instruments (0.1) 2.7 (2.5) 11.4 (Gains) losses reclassified to net income 1.4 (3.1) 2.9 (7.4) Less: tax (provision) benefit 0.3 (0.7) 0.7 (1.7) Net (gains) losses reclassified to net income 1.1 (2.4) 2.2 (5.7) Other comprehensive income (loss), net of tax 1.0 0.3 (0.3) 5.7 Ending balance $ (1.7) $ 3.6 $ (1.7) $ 3.6 Pension and other postretirement benefits Beginning balance $ 0.5 $ (3.1) $ 0.4 $ (3.2) Unrealized actuarial gains (losses) and prior service (costs) credits — — — — Less: tax provision (benefit) — — — — Net actuarial gains (losses) and prior service (costs) credits — — — — Amortization of actuarial and other (gains) losses, prior service cost (credits), and settlement and curtailment (income) charge reclassified to net income — — 0.1 0.1 Less: tax (provision) benefit — — — — Net actuarial and other (gains) losses, amortization of prior service cost (credits), and settlement and curtailment (income) charge reclassified to net income — — 0.1 0.1 Other comprehensive income (loss), net of tax — — 0.1 0.1 Ending balance $ 0.5 $ (3.1) $ 0.5 $ (3.1) Total AOCI ending balance at September 30 $ (53.9) $ (95.3) $ (53.9) $ (95.3) Reclassifications of accumulated other comprehensive income (loss) Three Months Ended September 30, Nine Months Ended September 30, In millions 2023 2022 2023 2022 Derivative instruments Currency exchange contracts (1) $ (0.2) $ 0.8 $ (0.7) $ 1.6 Natural gas contracts (2) (1.2) 2.3 (2.2) 4.1 Net investment hedge contract (3) — — — 1.7 Total before tax (1.4) 3.1 (2.9) 7.4 (Provision) benefit for income taxes 0.3 (0.7) 0.7 (1.7) Amount included in net income (loss) $ (1.1) $ 2.4 $ (2.2) $ 5.7 Pension and other post retirement benefits Amortization of prior service costs (2) $ — $ — $ 0.1 $ 0.1 Total before tax — — 0.1 0.1 (Provision) benefit for income taxes — — — — Amount included in net income (loss) $ — $ — $ 0.1 $ 0.1 ______________ (1) Included within "Net sales" on the condensed consolidated statement of operations. (2) Included within "Cost of sales" on the condensed consolidated statement of operations. (3) Included within "Interest expense, net" on the condensed consolidated statement of operations. |
Restructuring and Other (Inco_2
Restructuring and Other (Income) Charges, net (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Restructuring and Related Activities [Abstract] | |
Schedule of Restructuring and Related Costs | Detail on the restructuring charges and other (income) charges, net, is provided below. Three Months Ended September 30, Nine Months Ended September 30, In millions 2023 2022 2023 2022 Severance and other employee-related costs (1) $ 1.5 $ — $ 8.9 $ — Other (2) — — 2.7 — Restructuring charges 1.5 — 11.6 — Alternative Feedstock Transition 11.8 — 18.4 — North Charleston Plant Transition 9.8 — 12.7 — Business transformation costs 1.5 3.3 6.7 10.6 Other (income) charges, net 23.1 3.3 37.8 10.6 Total restructuring and other (income) charges, net $ 24.6 $ 3.3 $ 49.4 $ 10.6 _______________ (1) Represents severance and employee benefit charges. |
Income Taxes (Tables)
Income Taxes (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Income Tax Disclosure [Abstract] | |
Schedule of Effective Income Tax Rate Reconciliation | The effective tax rates, including discrete items, were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Effective tax rate 21.5 % 21.3 % 22.6 % 21.6 % The below table provides a reconciliation between our reported effective tax rates and the EAETR. Three Months Ended September 30, 2023 2022 In millions, except percentages Before tax Tax Effective tax rate % impact Before tax Tax Effective tax rate % impact Consolidated operations $ 32.1 $ 6.9 21.5 % $ 95.8 $ 20.4 21.3 % Discrete items: Restructuring and other (income) charges, net (1) 1.5 0.4 — — Sale of strategic investment (2) (0.1) — — — Other tax only discrete items — 2.3 — (0.3) Total discrete items 1.4 2.7 — (0.3) Consolidated operations, before discrete items $ 33.5 $ 9.6 $ 95.8 $ 20.1 EAETR (3) 28.7 % 21.0 % Nine Months Ended September 30, 2023 2022 In millions, except percentages Before tax Tax Effective tax rate % impact Before tax Tax Effective tax rate % impact Consolidated operations $ 143.9 $ 32.5 22.6 % $ 249.9 $ 53.9 21.6 % Discrete items: Restructuring and other (income) charges, net (1) 8.9 2.1 — — Sale of strategic investment (2) (19.3) (4.5) — — Other tax only discrete items — 2.8 — (1.1) Total discrete items (10.4) 0.4 — (1.1) Consolidated operations, before discrete items $ 133.5 $ 32.9 $ 249.9 $ 52.8 EAETR (3) 24.6 % 21.1 % _______________ (1) See Note 11 for further information. (2) See Note 4 for further information. |
Segment Information (Tables)
Segment Information (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Segment Reporting [Abstract] | |
Schedule of Segment Reporting Information | Three Months Ended September 30, Nine Months Ended September 30, In millions 2023 2022 2023 2022 Net sales Performance Materials $ 147.2 $ 144.9 $ 433.2 $ 415.7 Performance Chemicals 256.0 267.6 725.6 683.9 Advanced Polymer Technologies 42.8 69.5 161.6 185.1 Total net sales (1) $ 446.0 $ 482.0 $ 1,320.4 $ 1,284.7 Segment EBITDA (2) Performance Materials $ 74.5 $ 61.2 $ 208.5 $ 194.7 Performance Chemicals 24.7 65.7 89.9 158.2 Advanced Polymer Technologies 11.2 11.3 36.6 25.4 Total Segment EBITDA (2) $ 110.4 $ 138.2 $ 335.0 $ 378.3 Interest expense, net (23.1) (11.5) (64.3) (37.3) (Provision) benefit for income taxes (6.9) (20.4) (32.5) (53.9) Depreciation and amortization - Performance Materials (9.5) (8.9) (28.7) (26.7) Depreciation and amortization - Performance Chemicals (17.8) (9.7) (45.6) (29.4) Depreciation and amortization - Advanced Polymer Technologies (7.9) (7.1) (23.4) (22.5) Restructuring and other income (charges), net (3), (6) (20.0) (3.3) (43.8) (10.6) Acquisition and other-related costs (4) (0.1) (1.9) (4.6) (1.9) Gain on sale of strategic investment (5) 0.1 — 19.3 — Net income (loss) $ 25.2 $ 75.4 $ 111.4 $ 196.0 _______________ (1) Relates to external customers only, all intersegment sales and related profit have been eliminated in consolidation. (2) Segment EBITDA is the primary measure used by our chief operating decision maker to evaluate the performance of and allocate resources among our operating segments. Segment EBITDA is defined as segment revenue less segment operating expenses (segment operating expenses consist of costs of sales, selling, general and administrative expenses, research and technical expenses, other (income) expense, net, excluding depreciation and amortization). We have excluded the following items from segment EBITDA: interest expense, net, associated with corporate debt facilities, income taxes, depreciation, amortization, restructuring and other (income) charges, net, acquisition and other related costs, litigation verdict charges, (losses) and gains from the sale of strategic investments, and pension and postretirement settlement and curtailment (income) charges, net. (3) For the three and nine months ended September 30, 2023, charges of $1.3 million and $7.5 million relate to the Performance Materials segment, charges of $18.3 million and $34.0 million relate to the Performance Chemicals segment, and charges of $0.4 million and $2.3 million relate to the Advanced Polymer Technologies segment, respectively. For the three and nine months ended September 30, 2022, charges of $1.1 million and $3.7 million relate to the Performance Materials segment, charges of $1.7 million and $5.4 million relate to the Performance Chemicals segment, and charges of $0.5 million and $1.5 million relate to the Advanced Polymer Technologies segment, respectively. For more detail on the charges incurred see Note 11. (4) For the three and nine months ended September 30, 2023 and September 30, 2022, all charges relate to the acquisition and integration of Ozark Materials into the Performance Chemicals segment. For more detail see Note 16. (5) For the three and nine months ended September 30, 2023, gain on sale of strategic investment relates to the Performance Materials segment. For more detail see Note 4. |
Earnings (Loss) per Share (Tabl
Earnings (Loss) per Share (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Earnings Per Share [Abstract] | |
Schedule of Earnings Per Share, Basic and Diluted | Three Months Ended September 30, Nine Months Ended September 30, In millions, except share and per share data 2023 2022 2023 2022 Net income (loss) $ 25.2 $ 75.4 $ 111.4 $ 196.0 Basic and Diluted earnings (loss) per share Basic earnings (loss) per share $ 0.70 $ 1.99 $ 3.05 $ 5.10 Diluted earnings (loss) per share 0.69 1.98 3.03 5.06 Shares (in thousands) Weighted average number of common shares outstanding - Basic 36,225 37,839 36,585 38,451 Weighted average additional shares assuming conversion of potential common shares 162 295 226 269 Shares - diluted basis 36,387 38,134 36,811 38,720 |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share | The following average number of potential common shares were antidilutive, and therefore, were not included in the diluted earnings per share calculation: Three Months Ended September 30, Nine Months Ended September 30, In thousands 2023 2022 2023 2022 Average number of potential common shares - antidilutive 491 209 400 204 |
Acquisitions (Tables)
Acquisitions (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Business Combination and Asset Acquisition [Abstract] | |
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed | Purchase Price Allocation In millions Weighted Average Amortization Period Fair Value Cash and cash equivalents $ 8.0 Accounts receivable 28.7 Inventories (1) 48.4 Prepaid and other current assets 2.0 Property, plant and equipment 43.1 Intangible assets (2) Brands 10 years 15.0 Customer relationships 15 years 88.6 Developed technology 7 years 23.5 Goodwill (3) 109.8 Other assets, including operating leases 0.1 Total fair value of assets acquired $ 367.2 Accounts payable 13.9 Other liabilities 2.6 Total fair value of liabilities assumed $ 16.5 Less: Cash acquired (8.0) Plus: Amounts due from Seller 1.8 Total cash paid, less cash and restricted cash acquired $ 344.5 _______________ (1) Fair value of finished goods inventories acquired included a step-up in the value of $1.8 million, of which zero and $0.8 million was expensed in the three and nine months ended September 30, 2023. The expense is included within "Cost of sales" on the consolidated statement of operations. Inventories are accounted for on a FIFO basis of accounting. (2) The aggregate amortization expense was $2.7 million and $8.2 million for the three and nine months ended September 30, 2023. Estimated amortization expense is as follows: $2.7 million for the remainder of 2023, 2024 - $10.9 million, 2025 - $10.7 million, 2026 - $10.0 million, and 2027 - $10.0 million. (3) Goodwill largely consists of expected cost synergies and economies of scale resulting from the business combination. We expect the full amount to be deductible for income tax purposes. This acquired goodwill has been included within our Performance Chemicals reporting unit. See Note 7 for further information regarding our allocation of goodwill among our reporting units. |
Schedule of Acquisition Costs | The following table summarizes the costs incurred associated with these combined activities. Three Months Ended September 30, Nine Months Ended September 30, In millions 2023 2022 2023 2022 Legal and professional service fees $ 0.1 $ 1.9 $ 3.8 $ 1.9 Acquisition-related costs 0.1 1.9 3.8 1.9 Inventory fair value step-up amortization (1) — — 0.8 — Acquisition and other-related costs $ 0.1 $ 1.9 $ 4.6 $ 1.9 _______________ (1) Included within "Cost of sales" on the consolidated statement of operations. |
Background (Details)
Background (Details) | 9 Months Ended |
Sep. 30, 2023 segment | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Number of splits for Performance Chemicals | 2 |
Number of reporting segments | 3 |
Revenues - Disaggregation of Re
Revenues - Disaggregation of Revenue by Product Line (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Disaggregation of Revenue [Line Items] | ||||
Net sales | $ 446 | $ 482 | $ 1,320.4 | $ 1,284.7 |
Performance Materials segment | ||||
Disaggregation of Revenue [Line Items] | ||||
Net sales | 147.2 | 144.9 | 433.2 | 415.7 |
Performance Chemicals segment | ||||
Disaggregation of Revenue [Line Items] | ||||
Net sales | 256 | 267.6 | 725.6 | 683.9 |
Performance Chemicals segment | Pavement Technologies product line | ||||
Disaggregation of Revenue [Line Items] | ||||
Net sales | 129.7 | 88.3 | 316.4 | 194 |
Performance Chemicals segment | Industrial Specialties product line | ||||
Disaggregation of Revenue [Line Items] | ||||
Net sales | 126.3 | 179.3 | 409.2 | 489.9 |
Advanced Polymer Technologies segment | ||||
Disaggregation of Revenue [Line Items] | ||||
Net sales | $ 42.8 | $ 69.5 | $ 161.6 | $ 185.1 |
Revenues - Disaggregation of _2
Revenues - Disaggregation of Revenue by Geography (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Disaggregation of Revenue [Line Items] | ||||
Net sales | $ 446 | $ 482 | $ 1,320.4 | $ 1,284.7 |
North America | ||||
Disaggregation of Revenue [Line Items] | ||||
Net sales | 292.4 | 291.9 | 854.3 | 759.7 |
Asia Pacific | ||||
Disaggregation of Revenue [Line Items] | ||||
Net sales | 92.4 | 113.6 | 264.3 | 297.3 |
Europe, Middle East, and Africa | ||||
Disaggregation of Revenue [Line Items] | ||||
Net sales | 48.6 | 62.6 | 167.6 | 194 |
South America | ||||
Disaggregation of Revenue [Line Items] | ||||
Net sales | $ 12.6 | $ 13.9 | $ 34.2 | $ 33.7 |
Revenues - Contract assets (Det
Revenues - Contract assets (Details) - USD ($) | 9 Months Ended | |
Sep. 30, 2023 | Sep. 30, 2022 | |
Revenue from Contract with Customer [Abstract] | ||
Contract with customer, liability | $ 0 | $ 0 |
Change in Contract with Customer, Asset [Roll Forward] | ||
Beginning balance | 6,400,000 | 5,300,000 |
Contract asset additions | 13,200,000 | 14,300,000 |
Reclassification to accounts receivable, billed to customers | (11,700,000) | (13,400,000) |
Ending balance | $ 7,900,000 | $ 6,200,000 |
Fair Value Measurements - Measu
Fair Value Measurements - Measured on a Recurring Basis (Details) - USD ($) $ in Millions | Sep. 30, 2023 | Dec. 31, 2022 |
Liabilities: | ||
Life insurance owned by company | $ 13.8 | $ 13.3 |
Fair Value, Measurements, Recurring | ||
Assets: | ||
Deferred compensation plan investments | 2.4 | 1.1 |
Total assets | 2.4 | 1.1 |
Liabilities: | ||
Deferred compensation arrangement | 15.1 | 12.5 |
Total liabilities | 15.1 | 12.5 |
Fair Value, Measurements, Recurring | Level 1 | ||
Assets: | ||
Deferred compensation plan investments | 2.4 | 1.1 |
Total assets | 2.4 | 1.1 |
Liabilities: | ||
Deferred compensation arrangement | 15.1 | 12.5 |
Total liabilities | 15.1 | 12.5 |
Fair Value, Measurements, Recurring | Level 2 | ||
Assets: | ||
Deferred compensation plan investments | 0 | 0 |
Total assets | 0 | 0 |
Liabilities: | ||
Deferred compensation arrangement | 0 | 0 |
Total liabilities | 0 | 0 |
Fair Value, Measurements, Recurring | Level 3 | ||
Assets: | ||
Deferred compensation plan investments | 0 | 0 |
Total assets | 0 | 0 |
Liabilities: | ||
Deferred compensation arrangement | 0 | 0 |
Total liabilities | $ 0 | $ 0 |
Fair Value Measurements - Narra
Fair Value Measurements - Narrative (Details) - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||
Sep. 30, 2023 | Mar. 31, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Dec. 31, 2022 | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||
Proceeds from sale of strategic investment | $ 31,500,000 | $ 0 | ||||
Gain on sale of strategic investment | $ 100,000 | $ 19,300,000 | $ 0 | 19,300,000 | $ 0 | |
Impairment of equity investment | 0 | $ 0 | ||||
Equity securities where fair value is not readily determinable | 83,200,000 | 83,200,000 | 80,800,000 | |||
Debt securities, held-to-maturity, restricted | 80,200,000 | 80,200,000 | 78,000,000 | |||
Held-to-maturity, allowance for credit loss | 300,000 | 300,000 | 600,000 | |||
Restricted investment, restricted cash | 9,100,000 | 9,100,000 | 7,000,000 | |||
Restricted investments, at fair value | 76,400,000 | 76,400,000 | 74,700,000 | |||
Total debt including finance lease obligations | 1,478,300,000 | 1,478,300,000 | 1,479,900,000 | |||
Fair Value, Nonrecurring | ||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||
Assets, fair value | 0 | 0 | 0 | |||
Liabilities, fair value | 0 | 0 | 0 | |||
Privately Held Companies | ||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||
Equity method investments | 16,100,000 | 16,100,000 | 28,200,000 | |||
Impairment of equity investment | 0 | 0 | ||||
Debt Obligations | ||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||
Finance lease obligations | 101,300,000 | 101,300,000 | 101,900,000 | |||
Variable Interest Rate | ||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||
Total debt including finance lease obligations | 825,000,000 | 825,000,000 | 828,000,000 | |||
Senior Notes Issued 2018 | ||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||
Senior notes | 550,000,000 | 550,000,000 | 550,000,000 | |||
Senior Notes Issued 2018 | Level 2 | ||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||
Debt instrument, fair value | 453,900,000 | 453,900,000 | 471,800,000 | |||
Estimate of Fair Value Measurement | Debt Obligations | ||||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||||
Finance lease obligations | $ 103,600,000 | $ 103,600,000 | $ 106,200,000 |
Fair Value Measurements - Credi
Fair Value Measurements - Credit Ratings (Details) - USD ($) $ in Millions | Sep. 30, 2023 | Dec. 31, 2022 |
Debt Securities, Held-to-maturity, Credit Quality Indicator [Line Items] | ||
Debt securities, held-to-maturity | $ 71.4 | $ 71.6 |
AA+ | ||
Debt Securities, Held-to-maturity, Credit Quality Indicator [Line Items] | ||
Debt securities, held-to-maturity | 13.3 | 13.4 |
AA | ||
Debt Securities, Held-to-maturity, Credit Quality Indicator [Line Items] | ||
Debt securities, held-to-maturity | 0 | 0 |
AA- | ||
Debt Securities, Held-to-maturity, Credit Quality Indicator [Line Items] | ||
Debt securities, held-to-maturity | 10.4 | 10.5 |
A | ||
Debt Securities, Held-to-maturity, Credit Quality Indicator [Line Items] | ||
Debt securities, held-to-maturity | 13.2 | 13.2 |
A- | ||
Debt Securities, Held-to-maturity, Credit Quality Indicator [Line Items] | ||
Debt securities, held-to-maturity | 24.4 | 14.1 |
BBB+ | ||
Debt Securities, Held-to-maturity, Credit Quality Indicator [Line Items] | ||
Debt securities, held-to-maturity | $ 10.1 | $ 20.4 |
Inventories, net (Details)
Inventories, net (Details) - USD ($) $ in Millions | Sep. 30, 2023 | Dec. 31, 2022 |
Inventory, Net | ||
Raw materials | $ 172.9 | $ 106.7 |
Production materials, stores, and supplies | 29.9 | 27.9 |
Finished and in-process goods | 274.3 | 228.2 |
Subtotal | 477.1 | 362.8 |
Less: LIFO reserve | (90.4) | (27.8) |
Inventories, net | $ 386.7 | $ 335 |
Property, Plant and Equipment_3
Property, Plant and Equipment, net (Details) - USD ($) $ in Millions | Sep. 30, 2023 | Dec. 31, 2022 |
Property, Plant and Equipment | ||
Total cost | $ 1,565.8 | $ 1,509.4 |
Less: accumulated depreciation | (765.8) | (710.8) |
Property, plant, and equipment, net | 800 | 798.6 |
Machinery and equipment | ||
Property, Plant and Equipment | ||
Total cost | 1,218.1 | 1,162.7 |
Buildings and leasehold improvements | ||
Property, Plant and Equipment | ||
Total cost | 210.5 | 200.9 |
Land and land improvements | ||
Property, Plant and Equipment | ||
Total cost | 26.3 | 24.9 |
Construction in progress | ||
Property, Plant and Equipment | ||
Total cost | $ 110.9 | $ 120.9 |
Goodwill and Other Intangible_3
Goodwill and Other Intangible Assets, net - Narrative (Details) | 3 Months Ended | 9 Months Ended |
Sep. 30, 2023 USD ($) | Sep. 30, 2023 segment | |
Goodwill [Line Items] | ||
Number of splits for Performance Chemicals | segment | 2 | |
Goodwill, impairment loss | $ 0 | |
Performance Chemicals | ||
Goodwill [Line Items] | ||
Goodwill, impairment loss | $ 0 | |
Headroom, Goodwill Impairment | 19% | 19% |
Goodwill and Other Intangible_4
Goodwill and Other Intangible Assets, net - Carrying Amount (Details) $ in Millions | 9 Months Ended |
Sep. 30, 2023 USD ($) | |
Goodwill | |
Goodwill, beginning balance | $ 518.5 |
Segment change reallocation | 0 |
Foreign currency translation | 1.6 |
Goodwill, ending balance | 520.1 |
Performance Materials | |
Goodwill | |
Goodwill, beginning balance | 4.3 |
Segment change reallocation | 0 |
Foreign currency translation | 0 |
Goodwill, ending balance | 4.3 |
Performance Chemicals | |
Goodwill | |
Goodwill, beginning balance | 514.2 |
Segment change reallocation | (165) |
Foreign currency translation | 0 |
Goodwill, ending balance | 349.2 |
Advanced Polymer Technologies segment | |
Goodwill | |
Goodwill, beginning balance | 0 |
Segment change reallocation | 165 |
Foreign currency translation | 1.6 |
Goodwill, ending balance | $ 166.6 |
Goodwill and Other Intangible_5
Goodwill and Other Intangible Assets, net - Intangible Assets (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Dec. 31, 2022 | |
Finite-Lived Intangible Assets [Roll Forward] | |||||
Beginning balance, Gross Asset Value | $ 566.2 | ||||
Foreign currency translation | 2.6 | ||||
Ending balance, Gross Asset Value | $ 568.8 | 568.8 | |||
Beginning balance, Accumulated Amortization | (161.4) | ||||
Amortization | (10.5) | $ (7.9) | (31.4) | $ (23.8) | |
Foreign currency translation | (0.4) | ||||
Ending balance, Accumulated Amortization | (193.2) | (193.2) | |||
Other intangibles, net | 375.6 | 375.6 | $ 404.8 | ||
Customer contracts and relationships | |||||
Finite-Lived Intangible Assets [Roll Forward] | |||||
Beginning balance, Gross Asset Value | 388.5 | ||||
Foreign currency translation | 1.4 | ||||
Ending balance, Gross Asset Value | 389.9 | 389.9 | |||
Beginning balance, Accumulated Amortization | (113.8) | ||||
Amortization | (20) | ||||
Foreign currency translation | (0.3) | ||||
Ending balance, Accumulated Amortization | (134.1) | (134.1) | |||
Other intangibles, net | 255.8 | 255.8 | |||
Brands | |||||
Finite-Lived Intangible Assets [Roll Forward] | |||||
Beginning balance, Gross Asset Value | 89.2 | ||||
Foreign currency translation | 0.6 | ||||
Ending balance, Gross Asset Value | 89.8 | 89.8 | |||
Beginning balance, Accumulated Amortization | (23.9) | ||||
Amortization | (4.3) | ||||
Foreign currency translation | 0 | ||||
Ending balance, Accumulated Amortization | (28.2) | (28.2) | |||
Other intangibles, net | 61.6 | 61.6 | |||
Developed Technology | |||||
Finite-Lived Intangible Assets [Roll Forward] | |||||
Beginning balance, Gross Asset Value | 88.5 | ||||
Foreign currency translation | 0.6 | ||||
Ending balance, Gross Asset Value | 89.1 | 89.1 | |||
Beginning balance, Accumulated Amortization | (23.7) | ||||
Amortization | (7.1) | ||||
Foreign currency translation | (0.1) | ||||
Ending balance, Accumulated Amortization | (30.9) | (30.9) | |||
Other intangibles, net | $ 58.2 | $ 58.2 |
Goodwill and Other Intangible_6
Goodwill and Other Intangible Assets, net - Intangible Assets by Segments (Details) - USD ($) $ in Millions | Sep. 30, 2023 | Dec. 31, 2022 |
Finite-Lived Intangible Assets [Line Items] | ||
Other intangibles, net | $ 375.6 | $ 404.8 |
Performance Materials | ||
Finite-Lived Intangible Assets [Line Items] | ||
Other intangibles, net | 1.5 | 1.7 |
Performance Chemicals | ||
Finite-Lived Intangible Assets [Line Items] | ||
Other intangibles, net | 180.7 | 198 |
Advanced Polymer Technologies segment | ||
Finite-Lived Intangible Assets [Line Items] | ||
Other intangibles, net | $ 193.4 | $ 205.1 |
Goodwill and Other Intangible_7
Goodwill and Other Intangible Assets, net - Amortization (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Goodwill and Intangible Assets Disclosure [Abstract] | ||||
Amortization expense | $ 10.5 | $ 7.9 | $ 31.4 | $ 23.8 |
Goodwill and Other Intangible_8
Goodwill and Other Intangible Assets, net - Maturity (Details) $ in Millions | Sep. 30, 2023 USD ($) |
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity | |
2023 amortization expense | $ 10.5 |
2024 amortization expense | 41.6 |
2025 amortization expense | 41.3 |
2026 amortization expense | 40.6 |
2027 amortization expense | $ 40.6 |
Financial Instruments and Ris_3
Financial Instruments and Risk Management - Narrative (Details) mmbtus in Millions | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2023 USD ($) mmbtus | Sep. 30, 2022 USD ($) | Sep. 30, 2023 USD ($) mmbtus | Sep. 30, 2022 USD ($) | Dec. 31, 2022 USD ($) | |
Derivative [Line Items] | |||||
Interest expense, net | $ (23,100,000) | $ (11,500,000) | $ (64,300,000) | $ (37,300,000) | |
Cash flow hedged gains to be reclassified within 12 months | 2,100,000 | ||||
Derivative instruments | |||||
Derivative [Line Items] | |||||
Interest expense, net | 0 | 4,400,000 | |||
Reclassification out of Accumulated Other Comprehensive Income | Derivative instruments | |||||
Derivative [Line Items] | |||||
Interest expense, net | 0 | 100,000 | |||
Currency exchange contracts | |||||
Derivative [Line Items] | |||||
Interest and dividend | 0 | 100,000 | 0 | 2,800,000 | |
Currency exchange contracts | Derivative instruments | |||||
Derivative [Line Items] | |||||
Interest expense, net | 0 | 4,400,000 | |||
Currency exchange contracts | Reclassification out of Accumulated Other Comprehensive Income | Derivative instruments | |||||
Derivative [Line Items] | |||||
Interest expense, net | 0 | 100,000 | |||
Foreign currency hedging | |||||
Derivative [Line Items] | |||||
Derivative, notional amount | 6,000,000 | 6,000,000 | |||
Derivative, fair value, net asset (liability) | 100,000 | 100,000 | $ (500,000) | ||
Natural gas contracts | |||||
Derivative [Line Items] | |||||
Derivative, fair value, net asset (liability) | $ (800,000) | $ (800,000) | $ (1,600,000) | ||
Natural gas contracts | Swap | |||||
Derivative [Line Items] | |||||
Derivative, nonmonetary notional amount | mmbtus | 0.8 | 0.8 | |||
Natural gas contracts | Zero Cost Collar | |||||
Derivative [Line Items] | |||||
Derivative, nonmonetary notional amount | mmbtus | 0.1 | 0.1 | |||
Interest rate swap contracts | Derivative instruments | |||||
Derivative [Line Items] | |||||
Interest expense, net | $ 0 | 0 | $ 0 | 5,700,000 | |
Interest rate swap contracts | Reclassification out of Accumulated Other Comprehensive Income | Derivative instruments | |||||
Derivative [Line Items] | |||||
Interest expense, net | $ 0 | $ 0 | $ 0 | $ 1,700,000 |
Financial Instruments and Ris_4
Financial Instruments and Risk Management - Effect of Cash Flow and Net Investment Hedge Accounting on AOCI (Details) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] | ||||
Net sales | $ 446,000,000 | $ 482,000,000 | $ 1,320,400,000 | $ 1,284,700,000 |
Cost of sales | (317,000,000) | (305,700,000) | (908,000,000) | (820,000,000) |
Interest expense, net | (23,100,000) | (11,500,000) | (64,300,000) | (37,300,000) |
Interest expense, net | (1,300,000) | (2,000,000) | 13,900,000 | 1,000,000 |
Derivative instruments | ||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] | ||||
Interest expense, net | 0 | 4,400,000 | ||
Total | (200,000) | 3,500,000 | (3,300,000) | 14,900,000 |
Reclassifications from AOCI to net income | (1,400,000) | 3,100,000 | (2,900,000) | 7,400,000 |
Derivative instruments | Reclassification out of Accumulated Other Comprehensive Income | ||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] | ||||
Interest expense, net | 0 | 100,000 | ||
Total | (1,400,000) | 3,100,000 | (2,900,000) | 7,400,000 |
Accumulated Gain Loss Net Investment Hedging | ||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] | ||||
Total | 0 | 13,900,000 | ||
Accumulated Gain Loss Net Investment Hedging | Reclassification out of Accumulated Other Comprehensive Income | ||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] | ||||
Total | 0 | 2,800,000 | ||
Currency exchange contracts | ||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] | ||||
Reclassifications from AOCI to net income | 0 | 0 | 0 | 0 |
Currency exchange contracts | Derivative instruments | ||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] | ||||
Net sales | 100,000 | 500,000 | 0 | 1,800,000 |
Interest expense, net | 0 | 4,400,000 | ||
Currency exchange contracts | Derivative instruments | Reclassification out of Accumulated Other Comprehensive Income | ||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] | ||||
Net sales | (200,000) | 800,000 | (700,000) | 1,600,000 |
Interest expense, net | 0 | 100,000 | ||
Currency exchange contracts | Accumulated Gain Loss Net Investment Hedging | ||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] | ||||
Interest expense, net | 0 | 13,900,000 | ||
Currency exchange contracts | Accumulated Gain Loss Net Investment Hedging | Reclassification out of Accumulated Other Comprehensive Income | ||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] | ||||
Interest expense, net | 0 | 2,800,000 | ||
Natural gas contracts | Derivative instruments | ||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] | ||||
Cost of sales | (300,000) | 3,000,000 | (3,300,000) | 7,400,000 |
Natural gas contracts | Derivative instruments | Reclassification out of Accumulated Other Comprehensive Income | ||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] | ||||
Cost of sales | (1,200,000) | 2,300,000 | (2,200,000) | 4,100,000 |
Interest rate swap contracts | Derivative instruments | ||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] | ||||
Interest expense, net | 0 | 0 | 0 | 5,700,000 |
Interest rate swap contracts | Derivative instruments | Reclassification out of Accumulated Other Comprehensive Income | ||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] | ||||
Interest expense, net | $ 0 | $ 0 | $ 0 | $ 1,700,000 |
Financial Instruments and Ris_5
Financial Instruments and Risk Management - Fair Value of Hedging Contracts (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Millions | Sep. 30, 2023 | Dec. 31, 2022 |
Assets: | ||
Total assets | $ 0.5 | |
Liabilities: | ||
Total liabilities | 1.2 | $ 2.1 |
Level 1 | ||
Assets: | ||
Total assets | 0 | |
Liabilities: | ||
Total liabilities | 0 | 0 |
Level 2 | ||
Assets: | ||
Total assets | 0.5 | |
Liabilities: | ||
Total liabilities | 1.2 | 2.1 |
Level 3 | ||
Assets: | ||
Total assets | 0 | |
Liabilities: | ||
Total liabilities | 0 | 0 |
Currency exchange contracts | ||
Assets: | ||
Total assets | 0.5 | |
Liabilities: | ||
Total liabilities | 0.4 | 0.5 |
Currency exchange contracts | Level 1 | ||
Assets: | ||
Total assets | 0 | |
Liabilities: | ||
Total liabilities | 0 | 0 |
Currency exchange contracts | Level 2 | ||
Assets: | ||
Total assets | 0.5 | |
Liabilities: | ||
Total liabilities | 0.4 | 0.5 |
Currency exchange contracts | Level 3 | ||
Assets: | ||
Total assets | 0 | |
Liabilities: | ||
Total liabilities | 0 | 0 |
Natural gas contracts | ||
Liabilities: | ||
Total liabilities | 0.8 | 1.6 |
Natural gas contracts | Level 1 | ||
Liabilities: | ||
Total liabilities | 0 | 0 |
Natural gas contracts | Level 2 | ||
Liabilities: | ||
Total liabilities | 0.8 | 1.6 |
Natural gas contracts | Level 3 | ||
Liabilities: | ||
Total liabilities | $ 0 | $ 0 |
Debt including Finance Lease _3
Debt including Finance Lease Obligations - Long-term Debt (Details) - USD ($) $ in Millions | Sep. 30, 2023 | Dec. 31, 2022 |
Line of Credit Facility | ||
Total debt including finance lease obligations | $ 1,478.3 | $ 1,479.9 |
Less: debt issuance costs | 5.6 | 6.5 |
Total debt, including finance lease obligations, net of debt issuance costs | 1,472.7 | 1,473.4 |
Less: debt maturing within one year | 3 | 0.9 |
Long-term debt including finance lease obligations | 1,469.7 | 1,472.5 |
Revolving Credit Facility and other lines of credit | ||
Line of Credit Facility | ||
Total debt including finance lease obligations | 825 | 828 |
Letters of credit outstanding | 2.3 | 2.3 |
Available under the facility | $ 172.7 | 169.7 |
Senior Notes | 3.88% Senior Notes due 2028 | ||
Line of Credit Facility | ||
Stated rate | 3.88% | |
Total debt including finance lease obligations | $ 550 | 550 |
Finance lease obligations | ||
Line of Credit Facility | ||
Total debt including finance lease obligations | 101.3 | 101.9 |
Other notes payable | ||
Line of Credit Facility | ||
Total debt including finance lease obligations | $ 2 | $ 0 |
Debt including Finance Lease _4
Debt including Finance Lease Obligations - Narrative (Details) | Sep. 30, 2023 |
Line of Credit Facility | |
Leverage ratio, interest | 6.8 |
Term Loan | |
Line of Credit Facility | |
Actual leverage ratio | 2.5 |
Revolving Credit Facility | |
Line of Credit Facility | |
Leverage ratio potential increase | 4.5 |
Revolving Credit Facility | Maximum | |
Line of Credit Facility | |
Leverage ratio | 4 |
Revolving Credit Facility | Minimum | |
Line of Credit Facility | |
Leverage ratio, interest | 3 |
Equity - Rollforward of Equity
Equity - Rollforward of Equity (Details) - USD ($) | 3 Months Ended | 9 Months Ended | ||||||
Sep. 30, 2023 | Jun. 30, 2023 | Mar. 31, 2023 | Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Increase (Decrease) in Stockholders' Equity | ||||||||
Beginning balance (shares) | 37,298,989 | 37,298,989 | ||||||
Beginning balance | $ 714,100,000 | $ 725,700,000 | $ 698,300,000 | $ 654,300,000 | $ 686,100,000 | $ 673,800,000 | $ 698,300,000 | $ 673,800,000 |
Net income (loss) | 25,200,000 | 35,500,000 | 50,700,000 | 75,400,000 | 59,800,000 | 60,800,000 | 111,400,000 | 196,000,000 |
Other comprehensive income (loss) | (20,400,000) | 5,300,000 | 8,000,000 | (51,600,000) | (46,700,000) | (10,100,000) | ||
Common stock issued | (200,000) | |||||||
Exercise of stock options, net | 0 | 2,200,000 | 300,000 | 100,000 | 400,000 | |||
Tax payments related to vested restricted stock units | (200,000) | 0 | (4,500,000) | (200,000) | (1,800,000) | |||
Share repurchase program | 0 | (58,700,000) | (33,400,000) | (49,300,000) | (49,500,000) | (40,400,000) | $ (92,100,000) | (139,200,000) |
Share-based compensation plans | $ 0 | 6,300,000 | 4,400,000 | 5,000,000 | 4,700,000 | 3,400,000 | ||
Ending balance (shares) | 36,231,063 | 36,231,063 | ||||||
Ending balance | $ 718,700,000 | $ 714,100,000 | $ 725,700,000 | $ 633,900,000 | $ 654,300,000 | $ 686,100,000 | $ 718,700,000 | $ 633,900,000 |
Common Stock | ||||||||
Increase (Decrease) in Stockholders' Equity | ||||||||
Beginning balance (shares) | 43,430,000 | 43,408,000 | 43,228,000 | 43,200,000 | 43,180,000 | 43,102,000 | 43,228,000 | 43,102,000 |
Beginning balance | $ 400,000 | $ 400,000 | $ 400,000 | $ 400,000 | $ 400,000 | $ 400,000 | $ 400,000 | $ 400,000 |
Common stock issued (shares) | 13,000 | 22,000 | 139,000 | 8,000 | 18,000 | 42,000 | ||
Exercise of stock options, net (shares) | 0 | 0 | 41,000 | 5,000 | 2,000 | 36,000 | ||
Ending balance (shares) | 43,443,000 | 43,430,000 | 43,408,000 | 43,213,000 | 43,200,000 | 43,180,000 | 43,443,000 | 43,213,000 |
Ending balance | $ 400,000 | $ 400,000 | $ 400,000 | $ 400,000 | $ 400,000 | $ 400,000 | $ 400,000 | $ 400,000 |
Additional paid in capital | ||||||||
Increase (Decrease) in Stockholders' Equity | ||||||||
Beginning balance | 163,600,000 | 158,900,000 | 153,000,000 | 143,000,000 | 139,600,000 | 136,300,000 | 153,000,000 | 136,300,000 |
Exercise of stock options, net | 0 | 2,200,000 | 300,000 | 100,000 | 400,000 | |||
Share-based compensation plans | (1,000,000) | 4,700,000 | 3,700,000 | 4,200,000 | 3,300,000 | 2,900,000 | ||
Ending balance | 162,600,000 | 163,600,000 | 158,900,000 | 147,500,000 | 143,000,000 | 139,600,000 | 162,600,000 | 147,500,000 |
Retained earnings | ||||||||
Increase (Decrease) in Stockholders' Equity | ||||||||
Beginning balance | 1,093,900,000 | 1,058,400,000 | 1,007,700,000 | 916,700,000 | 856,900,000 | 796,100,000 | 1,007,700,000 | 796,100,000 |
Net income (loss) | 25,200,000 | 35,500,000 | 50,700,000 | 75,400,000 | 59,800,000 | 60,800,000 | ||
Ending balance | 1,119,100,000 | 1,093,900,000 | 1,058,400,000 | 992,100,000 | 916,700,000 | 856,900,000 | 1,119,100,000 | 992,100,000 |
Accumulated other comprehensive income (loss) | ||||||||
Increase (Decrease) in Stockholders' Equity | ||||||||
Beginning balance | (33,500,000) | (38,800,000) | (46,800,000) | (43,700,000) | 3,000,000 | 13,100,000 | (46,800,000) | 13,100,000 |
Other comprehensive income (loss) | (20,400,000) | 5,300,000 | 8,000,000 | (51,600,000) | (46,700,000) | (10,100,000) | ||
Ending balance | (53,900,000) | (33,500,000) | (38,800,000) | (95,300,000) | (43,700,000) | 3,000,000 | (53,900,000) | (95,300,000) |
Treasury stock | ||||||||
Increase (Decrease) in Stockholders' Equity | ||||||||
Beginning balance | (510,300,000) | (453,200,000) | (416,000,000) | (362,100,000) | (313,800,000) | (272,100,000) | (416,000,000) | (272,100,000) |
Common stock issued | (200,000) | |||||||
Tax payments related to vested restricted stock units | (200,000) | 0 | (4,500,000) | (200,000) | (1,800,000) | |||
Share repurchase program | 0 | (58,700,000) | (33,400,000) | (49,300,000) | (49,500,000) | (40,400,000) | ||
Share-based compensation plans | 1,000,000 | 1,600,000 | 700,000 | 800,000 | 1,400,000 | 500,000 | ||
Ending balance | $ (509,500,000) | $ (510,300,000) | $ (453,200,000) | $ (410,800,000) | $ (362,100,000) | $ (313,800,000) | $ (509,500,000) | $ (410,800,000) |
Equity - Rollforward of Accumul
Equity - Rollforward of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] | ||||
Beginning balance | $ 714.1 | $ 654.3 | $ 698.3 | $ 673.8 |
Other comprehensive income (loss), net of tax provision (benefit) of $0.2, $1.1, $(0.1), $5.0 | (20.4) | (51.6) | (7.1) | (108.4) |
Reclassifications of net actuarial and other (gain) loss and amortization of prior service cost, included in net income, net of tax of zero for all periods | 0 | 0 | 0.1 | 0.1 |
Ending balance | 718.7 | 633.9 | 718.7 | 633.9 |
Accumulated other comprehensive income (loss) | ||||
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] | ||||
Beginning balance | (33.5) | (43.7) | (46.8) | 13.1 |
Ending balance | (53.9) | (95.3) | (53.9) | (95.3) |
Foreign currency translation | ||||
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] | ||||
Beginning balance | (31.3) | (43.9) | (45.8) | 18.4 |
Net gains (losses) on foreign currency translation | (21.4) | (55.3) | (6.9) | (124.9) |
Gains (losses) on net investment hedges | 0 | 4.4 | 0 | 13.9 |
Less: tax provision (benefit) | 0 | 1 | 0 | 3.2 |
Net gains (losses) on net investment hedges | 0 | 3.4 | 0 | 10.7 |
Other comprehensive income (loss), net of tax provision (benefit) of $0.2, $1.1, $(0.1), $5.0 | (21.4) | (51.9) | (6.9) | (114.2) |
Ending balance | (52.7) | (95.8) | (52.7) | (95.8) |
Derivative instruments | ||||
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] | ||||
Beginning balance | (2.7) | 3.3 | (1.4) | (2.1) |
Gains (losses) on net investment hedges | (0.2) | 3.5 | (3.3) | 14.9 |
Less: tax provision (benefit) | (0.1) | 0.8 | (0.8) | 3.5 |
Net gains (losses) on derivative instruments | (0.1) | 2.7 | (2.5) | 11.4 |
(Gains) losses reclassified to net income | 1.4 | (3.1) | 2.9 | (7.4) |
Less: tax (provision) benefit | 0.3 | (0.7) | 0.7 | (1.7) |
Net (gains) losses reclassified to net income | 1.1 | (2.4) | 2.2 | (5.7) |
Other comprehensive income (loss), net of tax provision (benefit) of $0.2, $1.1, $(0.1), $5.0 | 1 | 0.3 | (0.3) | 5.7 |
Ending balance | (1.7) | 3.6 | (1.7) | 3.6 |
Pension and other postretirement benefits | ||||
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] | ||||
Beginning balance | 0.5 | (3.1) | 0.4 | (3.2) |
Gains (losses) on net investment hedges | 0 | 0 | 0.1 | 0.1 |
Less: tax provision (benefit) | 0 | 0 | 0 | 0 |
Net (gains) losses reclassified to net income | 0 | 0 | 0.1 | 0.1 |
Other comprehensive income (loss), net of tax provision (benefit) of $0.2, $1.1, $(0.1), $5.0 | 0 | 0 | 0.1 | 0.1 |
Unrealized actuarial gains (losses) and prior service (costs) credits | 0 | 0 | 0 | 0 |
Less: tax provision (benefit) | 0 | 0 | 0 | 0 |
Reclassifications of net actuarial and other (gain) loss and amortization of prior service cost, included in net income, net of tax of zero for all periods | 0 | 0 | 0 | 0 |
Ending balance | $ 0.5 | $ (3.1) | $ 0.5 | $ (3.1) |
Equity - Reclassification of AO
Equity - Reclassification of AOCI (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||||||
Sep. 30, 2023 | Jun. 30, 2023 | Mar. 31, 2023 | Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||||||
Net sales | $ 446 | $ 482 | $ 1,320.4 | $ 1,284.7 | ||||
Cost of sales | (317) | (305.7) | (908) | (820) | ||||
Interest expense, net | 23.1 | 11.5 | 64.3 | 37.3 | ||||
Total before tax | 32.1 | 95.8 | 143.9 | 249.9 | ||||
(Provision) benefit for income taxes | (6.9) | (20.4) | (32.5) | (53.9) | ||||
Amount included in net income (loss) | 25.2 | $ 35.5 | $ 50.7 | 75.4 | $ 59.8 | $ 60.8 | 111.4 | 196 |
Derivative instruments | ||||||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||||||
Interest expense, net | 0 | (4.4) | ||||||
Derivative instruments | Reclassification out of Accumulated Other Comprehensive Income | ||||||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||||||
Interest expense, net | 0 | (0.1) | ||||||
Total before tax | (1.4) | 3.1 | (2.9) | 7.4 | ||||
(Provision) benefit for income taxes | 0.3 | (0.7) | 0.7 | (1.7) | ||||
Amount included in net income (loss) | (1.1) | 2.4 | (2.2) | 5.7 | ||||
Amortization of prior service costs | Reclassification out of Accumulated Other Comprehensive Income | ||||||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||||||
Cost of sales | 0 | 0 | 0.1 | 0.1 | ||||
Pension and other postretirement benefits | Reclassification out of Accumulated Other Comprehensive Income | ||||||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||||||
Total before tax | 0 | 0 | 0.1 | 0.1 | ||||
(Provision) benefit for income taxes | 0 | 0 | 0 | 0 | ||||
Amount included in net income (loss) | 0 | 0 | 0.1 | 0.1 | ||||
Currency exchange contracts | Derivative instruments | Reclassification out of Accumulated Other Comprehensive Income | ||||||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||||||
Net sales | (0.2) | 0.8 | (0.7) | 1.6 | ||||
Natural gas contracts | Derivative instruments | ||||||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||||||
Cost of sales | (0.3) | 3 | (3.3) | 7.4 | ||||
Natural gas contracts | Derivative instruments | Reclassification out of Accumulated Other Comprehensive Income | ||||||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||||||
Cost of sales | (1.2) | 2.3 | (2.2) | 4.1 | ||||
Net investment hedge contract | Derivative instruments | Reclassification out of Accumulated Other Comprehensive Income | ||||||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||||||
Interest expense, net | $ 0 | $ 0 | $ 0 | $ 1.7 |
Equity - Share Repurchases (Det
Equity - Share Repurchases (Details) - USD ($) | 3 Months Ended | 9 Months Ended | |||||||
Sep. 30, 2023 | Jun. 30, 2023 | Mar. 31, 2023 | Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Jul. 25, 2022 | |
Equity [Abstract] | |||||||||
Amount remained unused under repurchase program | $ 353,400,000 | $ 353,400,000 | $ 500,000,000 | ||||||
Shares repurchased, excise tax | 800,000 | ||||||||
Shares repurchased | $ 0 | $ 58,700,000 | $ 33,400,000 | $ 49,300,000 | $ 49,500,000 | $ 40,400,000 | $ 92,100,000 | $ 139,200,000 | |
Shares repurchased (shares) | 0 | 697,523 | 1,269,373 | 2,027,206 | |||||
Shares acquired average cost per share (usd per share) | $ 0 | $ 70.75 | $ 71.93 | $ 68.68 |
Restructuring and Other (Inco_3
Restructuring and Other (Income) Charges, net - Restructuring (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Restructuring Cost and Reserve [Line Items] | ||||
Severance and other employee-related costs | $ 1.5 | $ 0 | $ 8.9 | $ 0 |
Other | 0 | 0 | 2.7 | 0 |
Restructuring charges | 1.5 | 0 | 11.6 | 0 |
Other (income) charges, net | 23.1 | 3.3 | 37.8 | 10.6 |
Total restructuring and other (income) charges, net | 24.6 | 3.3 | 49.4 | 10.6 |
Alternative Feedstock Transition | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Other (income) charges, net | 11.8 | 0 | 18.4 | 0 |
North Charleston Plant Transition | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Other (income) charges, net | 9.8 | 0 | 12.7 | 0 |
Business transformation costs | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Other (income) charges, net | $ 1.5 | $ 3.3 | $ 6.7 | $ 10.6 |
Restructuring and Other (Inco_4
Restructuring and Other (Income) Charges, net - Narrative (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | |
Restructuring Cost and Reserve [Line Items] | ||||||
Severance and other employee-related costs | $ 1.5 | $ 0 | $ 8.9 | $ 0 | ||
Other | 0 | 0 | 2.7 | 0 | ||
Restructuring reserve | 3.2 | 3.2 | $ 0.5 | |||
Other charges | 23.1 | 3.3 | 37.8 | 10.6 | ||
Alternative Fatty Acid Transition | ||||||
Restructuring Cost and Reserve [Line Items] | ||||||
Other charges | 11.8 | 0 | 18.4 | 0 | ||
North Charleston Plant Transition | ||||||
Restructuring Cost and Reserve [Line Items] | ||||||
Other charges | 9.8 | 0 | 12.7 | 0 | ||
Business transformation costs | ||||||
Restructuring Cost and Reserve [Line Items] | ||||||
Other charges | 1.5 | $ 3.3 | 6.7 | $ 10.6 | ||
Minimum | ||||||
Restructuring Cost and Reserve [Line Items] | ||||||
Restructuring expected cost | 12 | 12 | ||||
Maximum | ||||||
Restructuring Cost and Reserve [Line Items] | ||||||
Restructuring expected cost | 14 | 14 | ||||
Other Restructuring | Alternative Fatty Acid Transition | ||||||
Restructuring Cost and Reserve [Line Items] | ||||||
Incurred cost | 11.8 | 18.4 | ||||
Other Restructuring | North Charleston Plant Transition | ||||||
Restructuring Cost and Reserve [Line Items] | ||||||
Incurred cost | 9.8 | 12.7 | ||||
Other Restructuring | Minimum | Alternative Fatty Acid Transition | ||||||
Restructuring Cost and Reserve [Line Items] | ||||||
Restructuring expected cost | 20 | 20 | ||||
Other Restructuring | Minimum | North Charleston Plant Transition | ||||||
Restructuring Cost and Reserve [Line Items] | ||||||
Restructuring expected cost | 15 | 15 | ||||
Other Restructuring | Minimum | Forecast | Business transformation costs | ||||||
Restructuring Cost and Reserve [Line Items] | ||||||
Restructuring expected cost | $ 1 | |||||
Other Restructuring | Maximum | Alternative Fatty Acid Transition | ||||||
Restructuring Cost and Reserve [Line Items] | ||||||
Restructuring expected cost | 25 | 25 | ||||
Other Restructuring | Maximum | North Charleston Plant Transition | ||||||
Restructuring Cost and Reserve [Line Items] | ||||||
Restructuring expected cost | $ 20 | $ 20 | ||||
Other Restructuring | Maximum | Forecast | Business transformation costs | ||||||
Restructuring Cost and Reserve [Line Items] | ||||||
Restructuring expected cost | $ 2 |
Income Taxes - Effective tax ra
Income Taxes - Effective tax rate (Details) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Effective Income Tax Rate Reconciliation, Percent | ||||
Effective tax rate | 21.50% | 21.30% | 22.60% | 21.60% |
Income Taxes - Tax Reconciliati
Income Taxes - Tax Reconciliation (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Income Tax Disclosure [Abstract] | ||||
Effective tax rate | 21.50% | 21.30% | 22.60% | 21.60% |
Before tax | ||||
Income (loss) before income taxes | $ 32.1 | $ 95.8 | $ 143.9 | $ 249.9 |
Restructuring and other (income) charges, net | 1.5 | 0 | 8.9 | 0 |
Sale of strategic investment | (0.1) | 0 | (19.3) | 0 |
Total discrete items | 1.4 | 0 | (10.4) | 0 |
Consolidated operations, before discrete items | 33.5 | 95.8 | 133.5 | 249.9 |
Tax | ||||
Provision (benefit) for income taxes | 6.9 | 20.4 | 32.5 | 53.9 |
Restructuring and other (income) charges, net | 0.4 | 0 | 2.1 | 0 |
Sale of strategic investment | 0 | 0 | (4.5) | 0 |
Other tax only discrete items | 2.3 | (0.3) | 2.8 | (1.1) |
Total discrete items | 2.7 | (0.3) | 0.4 | (1.1) |
Consolidated operations, before discrete items | $ 9.6 | $ 20.1 | $ 32.9 | $ 52.8 |
EAETR | 28.70% | 21% | 24.60% | 21.10% |
Income Taxes - Narrative (Detai
Income Taxes - Narrative (Details) - USD ($) $ in Millions | Sep. 30, 2023 | Dec. 31, 2022 |
Income Tax Disclosure [Abstract] | ||
Deferred tax asset | $ 10.3 | $ 9.2 |
Commitment and Contingencies (D
Commitment and Contingencies (Details) $ in Millions | 1 Months Ended | |||
Sep. 15, 2021 USD ($) | Nov. 30, 2020 | Sep. 30, 2023 USD ($) | Feb. 14, 2019 claim | |
Loss Contingencies [Line Items] | ||||
Litigation settlement | $ 85 | |||
Final resolution, term | 30 months | |||
Loss contingency accrual | $ 85 | |||
BASF Lawsuit | ||||
Loss Contingencies [Line Items] | ||||
Claims for violations | claim | 2 | |||
BASF Lawsuit | Settled Litigation | ||||
Loss Contingencies [Line Items] | ||||
Awarded damages | $ 28.3 |
Segment Information - Net Sales
Segment Information - Net Sales and Segment Operating Profit (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||||||
Sep. 30, 2023 | Jun. 30, 2023 | Mar. 31, 2023 | Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Segment Reporting Information [Line Items] | ||||||||
Net sales | $ 446 | $ 482 | $ 1,320.4 | $ 1,284.7 | ||||
Segment Reporting Information, Profit (Loss) | ||||||||
Segment operating profits | 110.4 | 138.2 | 335 | 378.3 | ||||
Interest expense, net | (23.1) | (11.5) | (64.3) | (37.3) | ||||
(Provision) benefit for income taxes | (6.9) | (20.4) | (32.5) | (53.9) | ||||
Depreciation and amortization | (97.7) | (78.6) | ||||||
Restructuring and other income (charges), net | (20) | (3.3) | (43.8) | (10.6) | ||||
Acquisition and other related costs | (0.1) | (1.9) | (4.6) | (1.9) | ||||
Gain on sale of strategic investment | 0.1 | $ 19.3 | 0 | 19.3 | 0 | |||
Net income (loss) | 25.2 | $ 35.5 | $ 50.7 | 75.4 | $ 59.8 | $ 60.8 | 111.4 | 196 |
Restructuring and other (income) charges, net | 24.6 | 3.3 | 49.4 | 10.6 | ||||
Performance Materials | ||||||||
Segment Reporting Information [Line Items] | ||||||||
Net sales | 147.2 | 144.9 | 433.2 | 415.7 | ||||
Segment Reporting Information, Profit (Loss) | ||||||||
Segment operating profits | 74.5 | 61.2 | 208.5 | 194.7 | ||||
Depreciation and amortization | (9.5) | (8.9) | (28.7) | (26.7) | ||||
Restructuring and other (income) charges, net | 1.3 | 1.1 | 7.5 | 3.7 | ||||
Performance Chemicals | ||||||||
Segment Reporting Information [Line Items] | ||||||||
Net sales | 256 | 267.6 | 725.6 | 683.9 | ||||
Segment Reporting Information, Profit (Loss) | ||||||||
Segment operating profits | 24.7 | 65.7 | 89.9 | 158.2 | ||||
Depreciation and amortization | (17.8) | (9.7) | (45.6) | (29.4) | ||||
Restructuring and other (income) charges, net | 18.3 | 1.7 | 34 | 5.4 | ||||
Performance Chemicals | Alternative Fatty Acid Transition | ||||||||
Segment Reporting Information, Profit (Loss) | ||||||||
Depreciation and amortization | (4.6) | (5.6) | ||||||
Advanced Polymer Technologies | ||||||||
Segment Reporting Information [Line Items] | ||||||||
Net sales | 42.8 | 69.5 | 161.6 | 185.1 | ||||
Segment Reporting Information, Profit (Loss) | ||||||||
Segment operating profits | 11.2 | 11.3 | 36.6 | 25.4 | ||||
Depreciation and amortization | (7.9) | (7.1) | (23.4) | (22.5) | ||||
Restructuring and other (income) charges, net | $ 0.4 | $ 0.5 | $ 2.3 | $ 1.5 |
Earnings (Loss) per Share - Ear
Earnings (Loss) per Share - Earnings per share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions | 3 Months Ended | 9 Months Ended | ||||||
Sep. 30, 2023 | Jun. 30, 2023 | Mar. 31, 2023 | Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Earnings Per Share Reconciliation | ||||||||
Net income (loss) | $ 25.2 | $ 35.5 | $ 50.7 | $ 75.4 | $ 59.8 | $ 60.8 | $ 111.4 | $ 196 |
Basic and Diluted earnings (loss) per share | ||||||||
Basic earnings (loss) per share (usd per share) | $ 0.70 | $ 1.99 | $ 3.05 | $ 5.10 | ||||
Diluted earnings (loss) per share (usd per share) | $ 0.69 | $ 1.98 | $ 3.03 | $ 5.06 | ||||
Shares | ||||||||
Weighted average number of common shares outstanding - Basic (shares) | 36,225 | 37,839 | 36,585 | 38,451 | ||||
Weighted average additional shares assuming conversion of potential common shares (shares) | 162 | 295 | 226 | 269 | ||||
Shares - diluted basis (shares) | 36,387 | 38,134 | 36,811 | 38,720 |
Earnings (Loss) per Share - Ant
Earnings (Loss) per Share - Antidilutive (Details) - shares shares in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Earnings Per Share [Abstract] | ||||
Average number of potential common shares - antidilutive (shares) | 491 | 209 | 400 | 204 |
Acquisitions - Narrative (Detai
Acquisitions - Narrative (Details) $ in Millions | Oct. 03, 2022 USD ($) |
Ozark Materials | |
Business Acquisition [Line Items] | |
Payment for acquisition | $ 325 |
Acquisition - Purchase Price Al
Acquisition - Purchase Price Allocation (Details) - USD ($) | 3 Months Ended | 9 Months Ended | ||||
Oct. 03, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Dec. 31, 2022 | |
Net assets acquired based on fair values: | ||||||
Goodwill | $ 520,100,000 | $ 520,100,000 | $ 518,500,000 | |||
Amortization expense | 10,500,000 | $ 7,900,000 | 31,400,000 | $ 23,800,000 | ||
2023 amortization expense | 10,500,000 | 10,500,000 | ||||
2024 amortization expense | 41,600,000 | 41,600,000 | ||||
2025 amortization expense | 41,300,000 | 41,300,000 | ||||
2026 amortization expense | 40,600,000 | 40,600,000 | ||||
2027 amortization expense | 40,600,000 | 40,600,000 | ||||
Brands | ||||||
Net assets acquired based on fair values: | ||||||
Amortization expense | 4,300,000 | |||||
Ozark Materials | ||||||
Net assets acquired based on fair values: | ||||||
Cash and cash equivalents | $ 8,000,000 | |||||
Accounts receivable | 28,700,000 | |||||
Inventories | 48,400,000 | |||||
Prepaid and other current assets | 2,000,000 | |||||
Property, plant and equipment | 43,100,000 | |||||
Goodwill | 109,800,000 | |||||
Other assets, including operating leases | 100,000 | |||||
Total fair value of assets acquired | 367,200,000 | |||||
Accounts payable | 13,900,000 | |||||
Other liabilities | 2,600,000 | |||||
Total fair value of liabilities assumed | 16,500,000 | |||||
Less: Cash acquired | (8,000,000) | |||||
Plus: Amounts due from Seller | 1,800,000 | |||||
Total cash paid, less cash and restricted cash acquired | $ 344,500,000 | |||||
Inventory step up | 1,800,000 | 1,800,000 | ||||
Inventory fair value step-up amortization | 0 | 800,000 | ||||
Amortization expense | 2,700,000 | 8,200,000 | ||||
2023 amortization expense | 2,700,000 | 2,700,000 | ||||
2024 amortization expense | 10,900,000 | 10,900,000 | ||||
2025 amortization expense | 10,700,000 | 10,700,000 | ||||
2026 amortization expense | 10,000,000 | 10,000,000 | ||||
2027 amortization expense | $ 10,000,000 | $ 10,000,000 | ||||
Ozark Materials | Brands | ||||||
Business Acquisition [Line Items] | ||||||
Weighted Average Amortization Period | 10 years | |||||
Net assets acquired based on fair values: | ||||||
Intangible assets | $ 15,000,000 | |||||
Ozark Materials | Customer relationships | ||||||
Business Acquisition [Line Items] | ||||||
Weighted Average Amortization Period | 15 years | |||||
Net assets acquired based on fair values: | ||||||
Intangible assets | $ 88,600,000 | |||||
Ozark Materials | Foreign currency translation | ||||||
Business Acquisition [Line Items] | ||||||
Weighted Average Amortization Period | 7 years | |||||
Net assets acquired based on fair values: | ||||||
Intangible assets | $ 23,500,000 |
Acquisitions - Acquisition and
Acquisitions - Acquisition and Other Related Costs (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Business Acquisition [Line Items] | ||||
Acquisition-related costs | $ 0.1 | $ 1.9 | $ 3.8 | $ 1.9 |
Acquisition and other-related costs | 0.1 | 1.9 | 4.6 | 1.9 |
Acquisitions and Other Strategic Investments | ||||
Business Acquisition [Line Items] | ||||
Legal and professional service fees | 0.1 | 1.9 | 3.8 | 1.9 |
Acquisition-related costs | 0.1 | 1.9 | 3.8 | 1.9 |
Inventory fair value step-up amortization | 0 | 0 | 0.8 | 0 |
Acquisition and other-related costs | $ 0.1 | $ 1.9 | $ 4.6 | $ 1.9 |
Subsequent Events (Details)
Subsequent Events (Details) - USD ($) $ in Millions | 6 Months Ended | |||
Jun. 30, 2024 | Dec. 31, 2024 | Nov. 01, 2023 | Sep. 30, 2023 | |
Minimum | ||||
Subsequent Event [Line Items] | ||||
Restructuring expected cost | $ 12 | |||
Maximum | ||||
Subsequent Event [Line Items] | ||||
Restructuring expected cost | $ 14 | |||
Forecast | Minimum | ||||
Subsequent Event [Line Items] | ||||
Expected cost expected recognition | 50% | |||
Estimate of possible loss | $ 30 | |||
Forecast | Maximum | ||||
Subsequent Event [Line Items] | ||||
Expected cost expected recognition | 60% | |||
Estimate of possible loss | $ 80 | |||
Subsequent Event | ||||
Subsequent Event [Line Items] | ||||
Restructuring expected cost | $ 280 | |||
Expected cost, noncash | 180 | |||
Subsequent Event | Asset-Related | ||||
Subsequent Event [Line Items] | ||||
Restructuring expected cost | 180 | |||
Subsequent Event | Employee Severance and Other Related Costs | ||||
Subsequent Event [Line Items] | ||||
Restructuring expected cost | 15 | |||
Subsequent Event | Other Restructuring | ||||
Subsequent Event [Line Items] | ||||
Restructuring expected cost | $ 85 |